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Abstract 
 
Introduction:  
Due to the increase in healthcare costs, generic medicines have been adopted for used in both 
developed and developing countries. When a generic or ‘multisource interchangeable 
medicine’ is to be registered, studies that prove that the generic is equivalent to the Innovator 
Product (IP) are used. The generic medicine is required to prove that it will mirror the IP in 
terms of safety, quality and efficacy and, in South Africa, the Medicines Control Council 
(MCC) ensures that generic medicines meet these requirements. Generic medicines may be 
registered using bioequivalence data obtained from comparison with a domestic reference 
product (usually the local innovator product) or in certain cases, a foreign reference product 
(FRP). The bioequivalence data can either be from in vivo or in vitro studies. The MCC 
guidelines require that for modified release preparations, in vivo bioequivalence studies are 
done for approval of registration; the exception being if a proportionally higher dose has 
already been registered. No information is currently given to prescribers and dispensers or to 
the public about whether a generic product was registered against a foreign or domestic 
reference product. 
Aims and Objectives:  
1.) To determine the number of generic medicines in a predetermined sample registered using 
a FRP as comparator and to document the transparency of pharmaceutical companies when 
approached to disclose information regarding the registration of these products.  
2.) To describe and document the use of the Promotion of Access to Information Act (Act 2 
of 2000) [PAIA] from the perspective of a ‘layperson’ in the context of medicines’ 
regulation, in both private and public bodies. 
Methods:   
20 modified release and Biopharmaceutics Classification System (BCS) class IV products 
were selected from the ‘generics dictionary’ – a commercial publication – and letters were 
sent to the manufacturers of the products requesting information about the tests done to prove 
equivalence and whether they were performed against a domestic or foreign reference 
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product. The same information was also requested from the MCC. The requests were all 
made using the Promotion of Access to Information Act (PAIA). 
Results:  
Nine companies were represented by the 20 products chosen. Information was obtained about 
thirteen products. Ten of these products were registered using FRPs. Four products were 
registered based only on comparative dissolution studies. Four companies provided the 
requested information, two companies responded by refusing the requests and three did not 
respond at all. The MCC refused the request for information even after an internal appeal was 
lodged.  
Conclusions:  
The Promotion of Access to information Act was unsuccessful in obtaining information from 
the public body, and partly successful in obtaining it from the private bodies. While the title 
of the Act seems to indicate that the Act can be used to obtain information as such, it only 
provides for access to specified records. The MCC and the pharmaceutical companies 
involved in the study were under no obligation to provide the information as the request had 
not complied with PAIA requirements. The use of FRPs for registration is a reality in the 
pharmaceutical industry in South Africa. Neither the public nor healthcare professionals who 
prescribe medicines or who are involved in dispensing generic medicines as substitutes are 
aware of whether or not a FRP has been used to register a generic. Interchangeability cannot 
necessarily be guaranteed if the reference product was not proven equivalent to the local 
innovator product. It is debatable as to whether or not this information would be of any 
particular benefit to members of the public. Prescribers may choose to write ‘no substitution’ 
on their prescriptions if they were unconvinced that an FRP is acceptable. This could have 
consequences for healthcare costs. Dispensers are the most vulnerable in South Africa as they 
are obliged by law to substitute generic medicines when innovator medicines have been 
prescribed. Dispensers’ views on the acceptability of the use of FRPs can be seen as 
irrelevant. In the end, as this study demonstrates, the only option in the present situation is to 
rely entirely on the MCC’s rigour in assessing applications for registration of generic 
medicines.  
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Glossary 
Action research Action research is a form of enquiry that enables practitioners to evaluate 
their research process and make decisions about the next steps on an 
ongoing basis during the research. 
Bioavailability Absence of a significant difference in the rate and extent to which the active 
ingredient or active moiety in two pharmaceutically equivalent products 
becomes available at the site of drug action when administered at the same 
molar dose under similar conditions in an appropriately designed study 
Bioequivalence When two pharmaceutical products have bioavailabilities that are essentially 
the same in terms of peak Cmax and Tmax and AUC after administration of 
the same dose under the same conditions so that their effects with respect to 
both efficacy and safety can be expected to be essentially the same.  
Modified release 
preparation 
Dosage form for which the API release characteristics of time course and/or 
location are chosen to accomplish therapeutic or convenience objectives not 
offered by conventional dosage forms such as solutions, ointments, or 
promptly dissolving dosage forms. 
Delayed release 
preparation 
Dosage form that releases an API(s) at a time other than promptly after 
administration. 
Extended release 
preparation 
Dosage form is one that allows at least a twofold reduction in dosing 
frequency or significant increase in patient compliance or therapeutic 
performance as compared to that presented as a conventional dosage form 
Pharmaceutical 
alternatives 
Medicines that contain the same active moiety but differ either in chemical 
form (e.g. salt, ester) of that moiety or in the dosage form or strength, 
administered by the same route of administration but are otherwise not 
pharmaceutically equivalent. 
Pharmaceutical 
equivalents 
Medicines that contain the same amount of active substances, in the same 
dosage form, meet the same or comparable standards and are intended to be 
administered by the same route. 
Pharmacovigilance Pharmacovigilance is the science and activities relating to the detection, 
assessment, understanding, management and prevention of drug related 
adverse reactions and effects or any others possible drug-related problems. 
Therapeutic 
equivalence 
Medicines that are pharmaceutically equivalent or alternatives and after 
administration in the same molar dose, their effect with respect to both 
efficacy and safety are essentially the same as determined from appropriate 
bioequivalence, pharmacodynamic, clinical or in vitro studies. 
Transparency Frank, open or candid. Easily seen through, recognised, understood and 
clear. 
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Chapter 1: Introduction 
 
1.0 Introduction 
Medicines play a vital role in saving lives, restoring health, disease prevention and stopping 
epidemics. Governments and people therefore willingly spend money on them.[1] To add to 
that, medicines are the most widely used method of medical intervention and they are a 
cornerstone in the management of both chronic and acute diseases.[2] In Africa in particular, 
where access for vulnerable populations may be problematic, medicines may often be 
unaffordable, unavailable and unsafe due to poor quality.[3] The introduction and use of 
generic medicines has been noted as a breakthrough all across the globe. The use of generic 
medicines is being accepted and promoted from third world countries all the way to the first 
world countries.[4] The most important basis for the worldwide trust in medicines in general 
and more so for generic medicines is that they are of good quality, they are safe and effective 
and that their development, production, importation, exportation and subsequent distribution 
meets prescribed standards.[1] The bonus aspect about generic medicines is their cost. 
Generic medicines are cheaper and therefore present an opportunity for savings on medicines 
expenditure.[5,6] With that being said, the main goal of drug regulation is to guarantee the 
safety, efficacy and quality of drugs available to the public. Regulatory authorities are 
expected to observe a high level of efficiency, transparency and accountability as they carry 
out their function in drug regulation. This is essential currently so as to curb problems like the 
use of toxic, substandard and counterfeit drugs which are a waste of money and furthermore 
threaten the lives of consumers in both developing and developed countries.[1] 
A great deal of research has been done on generic medicines. It ranges from consumer and 
healthcare professionals’ acceptability and perspectives of the products to the actual 
processes involved for a product to eventually be registered as a generic medicine. Other 
researchers have looked at the possible negative aspects of generics and controversies that 
surround their use. Investigations have been made regarding their efficacy and quality in 
comparison to the Innovator or Brand name products. Queries have often been made and 
there have been efforts in assuring most of these are addressed from a regulatory and 
pharmaceutical industry perspective. The World Health Organization (WHO) has guidelines 
often adopted and modified by various countries to ensure generics are of a high quality and 
are safe.[7] 
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Eighty to eighty-six percent of the population of South Africa (SA) use the free public health 
facilities offered by the government for primary healthcare. If a cost is charged, it is often 
minimal.[3] This is of course in an effort to ensure access to and availability of medicines to 
the nation. The overall cost for the government to meet the healthcare needs of the nation is 
immense and the use of generics assists significantly in curbing the financial cost involved 
especially considering the prevalence of TB, HIV/AIDS and chronic diseases in SA.[3] For 
the procurement of medicines, the government promotes the use of generic medicines and 
works according to a public sector tender system which assists in lowering the cost.[8]   
1.1 Motivation for research 
Apart from ensuring that medicines that reach the consumers are of the appropriate standards 
in terms of safety, quality and efficacy, the role of the regulatory authority is also to provide 
appropriate and accurate information to the public.[1] The use of foreign reference products 
(FRPs) and comparative dissolution studies appear to be increasing in the registration of 
generic products in South Africa. The use of FRPs is permitted in the Pharmaceutical and 
Analytical guideline of the Medicines Control Council of South Africa (MCC).[9] 
Pharmaceutical companies must disclose the details of the reference product used to the MCC 
for purposes of registration. The information currently given to the prescribers, dispensers / 
pharmacists and the public about whether a domestic reference product (DRP) or a FRP was 
used for registration of a generic product is not provided by the MCC. Pharmacists are 
obliged by the Medicines and Related Substances Act, Act 101 of 1965 (Section 22F) to offer 
patients generic alternatives to prescribed medicines. The National Drug Policy 2006 (NDP) 
also states that ‘Patients have the right to make informed decisions concerning their own 
health, including a choice for generic medicines.’[8] To make an informed decision, patients 
would need to be sure that the product they are receiving is of equivalent safety, quality and 
efficacy as the domestic innovator product (IP). It is also important for the prescribers and 
dispensers to have full confidence that the generic medicines that they are prescribing, 
dispensing and substituting have been proven to be equivalent to the local IP. 
How and when the use of FRPs began is not clear. A senior member of staff, who has been 
involved in medicines regulation suspects that the use of FRPs as comparators may have 
stemmed from the apartheid era in South Africa when economic sanctions were imposed. It is 
assumed that an unintended consequence of sanctions was the continued suppression of the 
pharmaceutical manufacturing industry (amongst other industries) post-apartheid.[10,11] As 
South Africa had an active regulatory authority at that stage, the WHO did not push 
medicines through as they would do in countries that do not have an active medicines 
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regulatory authority. In contrast to that point of view it is noted that several multinational 
pharmaceutical ‘giants’ for example Novartis, Merck and Roche settled in South Africa 
during the apartheid era. One source claims that the industry flourished to such an extent that 
it became an economic pillar for the apartheid government.[12] Post apartheid, the use of 
FRPs seems to have remained a reality for the pharmaceutical industry. The use of FRPs as 
comparators in the registration of generic products is an area that has not been widely 
researched in South Africa, and is a key aspect of this study. 
In considering the requirements that generic medicines are safe, effective and equivalent to 
the domestic IP, the use of the FRPs as comparators may compromise these requirements. As 
generic substitution is based on the concept on interchangeability, there are concerns whether 
products registered against a FRP are interchangeable with the local innovator product in 
clinical practice. There is ideally also a need for transparency about the use of FRPs from 
pharmaceutical companies who apply for registration of the new generic products, and from 
the regulatory authority that approves the registration of these products i.e. the MCC. The 
MCC is required to protect the public when it comes to medicines. It ensures that whatever is 
placed on the market has met acceptable requirements for safety, quality and efficacy.[13] 
This is consistent with the WHO requirements for regulatory authorities’ duties.[1] 
The pharmaceutical industry is one of the most profitable industries in the world. A financial 
motive drives it.[14,15] This may result in possible compromises on certain values.[14-16] 
The need for more affordable healthcare may also cause regulatory authorities and 
pharmaceutical companies to overlook certain critical issues in medicine registration, for 
example the tests used to ascertain the safety and efficacy of the drugs.[14] Multiple disasters 
have been recorded in history as a result of ‘loopholes’ in drug regulation. Examples include 
the death of 107 children in the United States in the 1930’s because of sulphanilamide; the 
Thalidomide disaster in the 1960’s that resulted in birth defects in children; and in India and 
Haiti multiple deaths were recorded as a result of medicines contaminated with diethylene 
glycol in the 1990’s. Bringing it closer to home, in Niger 2500 deaths were recorded due to 
fake vaccines given for meningitis.[1] This shows the gravity and importance of effective 
drug regulation. Effective drug regulation is a tool that can tackle and possibly prevent such 
disasters.[1] This study looks at both the MCC and pharmaceutical companies and documents 
some issues concerning the requirements for proof of equivalence in generic medicines 
registration; as well as the use of FRPs. 
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1.2 Aims and Objectives 
 
The Aim of the study is to investigate the use of FRPs in the registration of generic medicines 
in South Africa. 
The objectives of the research include: 
• To determine the number of controlled release and BCS Class IV products registered 
against FRPs in a predetermined sample of 20 multisource interchangeable (generic) 
medicines. 
• To document the willingness of pharmaceutical companies to provide information 
about the registration of the selected generic products.  
• To document the willingness of the MCC to provide information about the 
registration of the selected generic products.  
• To describe and document the use of the Promotion of Access to Information Act, 
(Act 2 of 2000) from a ‘laypersons’ perspective in meeting the above objectives.  
 
1.3 Layout of Chapters 
Following this introductory chapter is a review of the literature (chapter two). The literature 
review gives a background to the research. It explains what generic medicines are, their 
importance and details regarding their registration locally and globally. It highlights local and 
global perspectives that patients and healthcare professionals have about generic medicines. 
The review also highlights controversies raised around generic medicines in the media and in 
pharmaceutical and scientific arenas. It gives an overview of methods involved in testing for 
equivalence and the guidelines set up to govern registration of these products. It discusses 
what foreign reference products are and their use in the registration of medicines. A history of 
the use of reference products and tests used in establishing equivalence of generic medicines 
in South Africa is given using a range of MCC documents. The chapter also addresses the 
concept of transparency and its application in the pharmaceutical industry. Details are 
provided about the Promotion of Access to Information Act and its use in obtaining 
information from both public and private institutions.  
Chapter three describes the methodology. It describes and explains the methods chosen for 
use in data collection so as to achieve the aims and objectives of this study. It gives details as 
to how the data were collected in sequential steps for all the participants in the study.  
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The results are presented in chapter four. In this chapter, the communication between the 
investigator and the company correspondents is narrated. The chapter also describes how 
obstacles faced in the data collection were handled and overcome in line with the research 
methodology used. Due to a confidentiality agreement, no names of correspondents, 
companies and pharmaceutical products are disclosed.  
The results are analysed, interpreted and discussed in chapter five. Finally chapter six gives a 
summary of the study and draws some conclusions. It also mentions limitations of the study 
and makes recommendations based on the findings of the research and literature. Possible 
future areas for study are suggested. 
The researcher is also referred to as the ‘investigator’ in the dissertation. The terms generic 
medicines and multi-source interchangeable medicines are used interchangeably.  
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Chapter 2: Literature review 
 
2.0 Regulation of Medicines 
In South Africa, the regulation of medicines involves overseeing a wide range of processes 
including development of products, manufacturing, clinical trials, registration, the use of 
unregistered medicines, post marketing surveillance, licensing of wholesalers and 
distributors, premises, people and practices, inspections of manufacturing facilities and 
distribution channels, product assessment and registration, adverse drug reaction monitoring 
and control of drug promotion and advertising. These are consistent with the WHO 
descriptions.[1,17] The term ‘product’ refers to new pharmaceutical medicines e.g. new 
chemical entities (NCEs) but also to generic or interchangeable multisource medicines. In 
some countries registration of medicines, which occurs in South Africa, is referred to as 
licensing or drug approval.[18] 
2.1 Definition of a generic medicine 
Generic medicines or interchangeable multi-source medicines are medicines that ‘contain the 
same active substances which are identical in strength and concentration, dosage form and 
route of administration and meet the same comparable standards which comply with the 
requirements of therapeutic equivalence as prescribed.’[19] The WHO defines a generic 
product as a multisource pharmaceutical product which is intended to be interchangeable with 
the originator or other comparators. It is usually manufactured without a licence from the 
innovator company and marketed after the expiry of patent or other exclusivity rights.[20] 
The United States Food and Drug Administration (FDA) define a generic medicine as being a 
medicine that is identical or bioequivalent1, to a brand drug in dosage form, safety and 
strength, route of administration, quality, performance characteristics and intended use.[3] 
Another less official but simpler definition of a generic is: ‘...a faithful imitation of a mature 
drug’ which is intended to be interchangeable with the originator.[21] All the definitions of a 
generic product found in literature can generally be summed up by saying generics are copies 
of the original products meant to behave in a similar manner and produced after expiry of the 
patent by other manufactures.[4] The Innovator product (IP) or brand drug would be the drug 
the generic would be interchangeable with, and therapeutically equivalent to in clinical 
                                                             
1  See glossary  
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practice. The bottom line is that the generic is not any better, nor any worse in any regard 
when compared to the IP.[22] 
2.2 The use of generic medicines 
The drive for generic prescribing and substitution globally has mainly been for financial 
reasons. The cost of healthcare has escalated all over the world and this is partly due to the 
increased cost of drugs.[3,4] Generic prescribing and substitution have been identified as a 
means of reducing the healthcare costs in South Africa and internationally, both in 
developing and developed countries.[4,23,24] The IP is more expensive compared to the 
generics due to the high cost of drug development in bringing a new product to the market. In 
1987 this cost was estimated to be USD 114 million.[25] In 2006 the cost was estimated to be 
over USD 800 million with the cost of clinical trials contributing significantly to these 
figures.[15,25,26] In 2010, the Pharmaceutical Research Manufactures of America stated that 
it cost approximately $1 billion for a product to reach the market.[27] The cost of an IP is 
high so as to recover costs used in development, make a profit and re-invest in further drug 
development.[27-30] Figure 2.1 below shows a flowchart illustrating the drug development 
process. This process may take 10-20 years.[31,32] 
 
Figure 2.1: Drug discovery and development flowchart2 
Generic medicines can only be registered once the patent of the IP expires; and registration 
would normally require less time and less money.[29] All the preliminary work that happens 
prior to registration of a new product i.e. identifying a hit compound and lead compound, pre-
clinical trials and the three phases of clinical trials are normally bypassed when generic 
medicines are registered.  
 
 
                                                             
2  Summary of the drug development process constructed and adapted from: 
http://www.locumusa.com/pdf/handbooks/flow.pdf  [Accessed  2011 November] 
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2.2.1 Increasing accessibility to medicines 
The use of generics is particularly important in developing countries as they are more 
affordable to the population; but they’re also important in developed countries like the United 
States of America (USA) and Europe.[2,23,33] Apparently many patients in the USA take 
less than the prescribed dose in efforts to make their medicines last longer. Some patients do 
not even buy the medicines because of inflated costs. Shifting to lower cost generics therefore 
has the potential to not only improve affordability and accessibility to medicines but also 
promote adherence.[2] Multiple chain pharmacies in the USA have adopted a $4 generic drug 
program which allows consumers to save money when purchasing their medicines monthly. 
The chain pharmacies, which include ‘Walmart’ and ‘Target’ make use of these low cost 
medicines in increasing affordability and access to medicines for low income patients and 
patients with chronic diseases.[2] A similar ‘scheme’ does not yet exist in South Africa. 
In Kenya, where generic medicines make up to 90% of the medicines consumed, their 
Constitutional Court in 2008 barred the government from implementing the Anti-Counterfeit 
Act of 2008 as it also applied to generic medicines. The Act confused Intellectual property 
rights (IPR) and quality issues hence defining legitimate generic drugs as counterfeits.[33] 
Three petitioners protested that this legislature denied them access to affordable and essential 
medicines and the Judge agreed that the wording in the Act was ‘rather vague’ resulting in 
the confusion between counterfeit and generic medicines. The final ruling ensured that the 
importation and distribution of generic medicines in Kenya continued so as to maintain 
accessibility to medicines.[33] 
2.3 How generic medicines reduce healthcare costs 
Innovator drug companies generally try to make as much money as possible from their 
products before the patents expire and generic companies are permitted to apply for 
registration for that same product.[27] As the costs of generic medicine production and 
development prior to registration are significantly lower than those of the IP, this in part 
contributes to their lower prices. Not needing to conduct clinical trials significantly reduces 
the costs of development of generics. As patents expire, and other manufacturers make 
generics which compete for the market, a further lowering of prices occurs.[23,34] The IP 
itself is often forced to lower its price as well.[27] 
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2.4 South African healthcare system 
South Africa has a two-tier healthcare system i.e. the private and the public sectors. The 
private sector is funded mainly by out-of-pocket spending and medical aid schemes while the 
public sector is funded mainly by the government. This is from general tax and other 
revenues.[8,35] South Africa’s population was set at over 50 million in July 2011,[36] and 
the public sector caters for approximately 80-86% of these people, providing medicines for 
free or at a minimal charge at primary healthcare facilities.[6,8] In 2009, 5.6 million people 
were estimated to be living with HIV/AIDS in SA and a 2010 report from the United Nations 
(UN) still indicates SA as being one of the most severely affected countries in Southern 
Africa.[37,38] In addition, SA is one of the leading countries in the world with regards to TB 
infection.[39] In terms of chronic conditions: antihypertensives, hypolipidaemic agents and 
antidepressants were the three therapeutic groups contributing the most in terms of healthcare 
expenditure in 2004, 2005 and 2006.[35,40]  
 
Considering the high prevalence of HIV/AIDS, TB and various chronic diseases in SA, 
providing free healthcare to such a large proportion of the population is a financial burden on 
the government. Despite this, it was noted that in 1990 the private sector was responsible for 
80% of the country's total expenditure on drugs, while 60-70% of the total volume of 
pharmaceuticals was consumed in the public sector.[35] In 2006 the minority private sector 
consumed over half of the country’s annual healthcare expenditure.[35] Generic medicines 
contribute in making the provision of free healthcare possible.[41] The generics industry has 
made medicines more affordable and hence more accessible to government and ultimately to 
individuals.[8,23,41] 
 
The Department of Health (DoH) procures medicines via state tender schemes which are 
described in detail in the National Drug Policy of 1996 (NDP). To ensure cost effectiveness 
both national and international tendering is permitted. This allows the state to purchase in 
bulk and at a fixed price for set periods.[8,23] This system allows for price negotiations and 
once the contract is awarded and signed the provincial authorities make arrangements to get 
stock from the suppliers.[8] Preference is generally given to national tenders but regardless of 
that, international tenders will be considered in an effort to keep costs as low as possible.[8] 
The competition results in lower prices. 
Several generic medicines manufacturers have been established in SA. Some of these are also 
distributors of products that have been manufactured elsewhere. Aspen Holdings, which is 
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one of the leading generic manufacturers in SA also distributes generic products acquired 
from India. In 2010, Aspen restructured its oncology joint venture with Strides Arcolab, an 
Indian pharmaceutical company. The joint venture entails that Strides would license its 
existing and future oncology products to Aspen to distribute.[42] India has emerged as the 
leading supplier of generic medicines to developing countries.[43] It has been observed that a 
significant quantity of generic antiretrovirals (ARVs) for developing countries are produced 
and exported from India. It is claimed that changes in the availability of generic medicines 
from India would affect both affordability and availability of medicines elsewhere.[43] Cipla 
Medpro South Africa Limited is another generics company which has an arrangement with 
Biomab, which in turn is a division of the Chinese pharmaceutical company Desano Pharma. 
The deal gives Cipla Medpro access to the biotech medicines developed by Biomab, 
including biosimilars and monoclonal antibody medications.[44] 
2.4.1 Generic utilisation in South Africa 
The National Association of Pharmaceutical Manufacturers (NAPM) has been on a drive to 
raise awareness with regards to the use of generic medicines here in South Africa. In 1996, a 
low rate of 13.9% was noted for generic substitution.[4] In 2003 NAPM believed that SA was 
still lagging behind in the use of generic medicines as they were making up only 20% of the 
volume of all prescriptions. The organisation believes that using more generics could save the 
country up to 24 million Rand.[4] In December 2006, the generic utilisation of SA in terms of 
volume had increased from 35.3% in December 2002 to 53.5%.[45]  
In terms of financial gain, a study in 1990 indicated that a potential saving of between 9.9% – 
59.7% ( mean 41.1%) was possible with generic substitution in SA. In 1996, further research 
observed that generic substitution could reduce medicine costs by a further 10%.[23,35] To 
promote the use of generic medicines, the 2003 amendment of the Medicines and Related 
Substances Act, Act 101 of 1965 (MARS) Section 22F3 requires that Pharmacists must offer 
                                                             
3  22F Generic substitution  
 (1) Subject to subsections (2), (3) and (4), a pharmacist shall-  
 (a) inform all members of the public who visit his or her pharmacy with a 
prescription for dispensing, of the benefits of the substitution for a branded 
medicine of an interchangeable multi-source medicine; and  
 (b) dispense an interchangeable multi-source medicine instead of the medicine 
prescribed by a medical practitioner, dentist, practitioner, nurse or other person 
registered under the Health Professions Act, 1974, unless expressly forbidden by 
the patient to do so.  
 (2) If a pharmacist is forbidden as contemplated in subsection (1) (b), that fact shall be 
noted by the pharmacist on the prescription.  
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patients generic alternatives to prescribed medicines.[19] Similar legislation has been adopted 
by various other countries across the globe including Finland, Japan and Iraq.[47-49]  
The use of generic medicines was envisaged in the National Drug Policy (NDP) of 1996 as 
follows: 
4.2 The use of generic drugs 
The use of interchangeable multi-source pharmaceutical products (IMPP), using the 
international non-proprietary name (INN), or generic name, is a recommended step to reduce 
drug costs and expenditure. It also contributes to a sound system of procurement and 
distribution, drug information and rational use at every level of the healthcare system. 
• The availability of generic, essential drugs will be encouraged through the 
implementation of incentives that favour generic drugs and their production in the 
country. 
• The policy will aim at achieving generic prescribing in both the public and private 
sectors. Until this aim is achieved, generic substitution will be allowed, through 
legislation, in the public and the private sector.  
• It will be incumbent on the pharmacist, prior to dispensing a prescription, to inform 
the patient on the benefits of generic substitution and to ensure that substitution takes 
place with the patient’s full understanding and consent. 
• Patients have the right to make informed decisions concerning their own health, 
including a choice for generic drugs. 
• A regularly updated list of products that cannot be substituted will be prepared and 
disseminated by the MCC. 
 
In 2009, the Department of Health in the UK was also considering automatic generic 
substitution. This would mean that when a dispenser received a prescription with a brand 
name product, he/she would be free to substitute and dispense a generic version of the 
medicine.[50] 
 
2.4.2 Global economic impact of generic utilisation 
The European Union (EU) has estimated that generic substitution in their primary care 
systems will save £45million a year.[51] With a generic prescribing rate of 83% recorded in 
                                                                                                                                                                                             
 (3) When an interchangeable multi-source medicine is dispensed by a pharmacist he or 
she shall note the brand name or where no such brand name exists, the name of the 
manufacturer of that interchangeable multi-source medicine in the prescription book.  
 (4) A pharmacist shall not sell an interchangeable multi-source medicine-  
 (a) if the person prescribing the medicine has written in his or her own hand on 
the prescription the words 'no substitution' next to the item prescribed;   
 (b) if the retail price of the interchangeable multi-source medicine is higher than 
that of the prescribed medicine; or  
 (c) where the product has been declared not substitutable by the council. (emphasis 
added) 
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2010, Europe has one of the highest rates of generic usage.[50,52] In 2009 Canada’s 
healthcare system saved more than $4 billion through using generic prescription 
medicines.[41] In 2007, in the USA, 63% of all prescription drugs were generic medicines. 
Generic medicines save consumers and purchasers of these prescription drugs tens of millions 
of dollars per year.[5,53] Estimates from IMS Health4 in the USA are that the US healthcare 
system, over the four years from 2011, will save at least $70 billion due to the replacement of 
brand name drugs by generics. However with the introduction of the Affordable Care Act 
extraordinary increases in brand name drugs, especially those with patents about to expire, 
have occurred.[27] The Japanese government strongly supports generic substitution as it was 
estimated it would reduce total drug costs by 1,3 Trillion JPY5.[48] In Finland, where 
generics were introduced in 2003, consumers have the potential to save up to 60% if generic 
substitution is fully implemented.[47] 
2.5 Consumer acceptability of generic medicines 
 
In general while governments all over the world have welcomed generic medicines in terms 
of possible financial benefits, some consumers still have reservations regarding generic 
medicines. The common issues that are stated regarding generic medicines are as follows: 
• Mistrust of the generics 
• The lower prices are often associated with poor quality 
• Lack of awareness regarding generics 
• Claims of differences in safety, quality and effectiveness.[24,34,41,49] 
 
2.5.1 South Africa 
A small case study conducted by third year pharmacy students in 2007 at Rhodes University 
on 23 university students, compared to 18 older individuals showed a lack of appreciation of 
the benefits of generic medicines among the older participants.[54] A study conducted on a 
national level in SA showed that the low cost of generics was often associated with 
perceptions of poor quality and they were generally treated with suspicion even when 
provided by the State.[6] ‘...This body does not want free medicines...’ was one of the 
statements made by the participants. The study however also showed that informed patients 
were more likely to use generics.[6] The respondents in the study indicated that they would 
opt for generics if their medical practitioners, rather than pharmacists recommended the 
generic medicines as they trusted doctors more regarding generic medicine use.[6] 
                                                             
4  A provider of information services for the healthcare industry 
5  Japanese Yen 
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2.5.2 Beyond South African borders 
In 2008 Japan introduced a policy to encourage generic substitution. As in SA the policy 
allows a pharmacist to substitute prescribed medicines unless the prescriber strictly states a 
refusal for substitution. Elderly Japanese consumers were sceptical about generic medicines’ 
safety and effectiveness.[48]. In Iraq, a study on patients’ perceptions of generics showed a 
distinct lack of awareness of generic medicines among Iraqi consumers.[49] Some of the 
barriers to acceptance identified were a familiarity with the IP and an unwillingness to 
change, prescribers’ inclinations to prescribing only IP and fear of counterfeit medicines.[49]  
In Melbourne Australia, an additional problem cited which reduced acceptability of generic 
medicines was the occurrence of adverse drug reactions (ADRs) experienced by some 
patients when a change from an IP to a generic was made.[55] Certain generics were also 
reported to be causing problems on a customer advocacy website in the USA6. Most of the 
stories shared on the website were from patients who had been switched to a generic from a 
brand name or IP. Some experienced side effects while others found that the symptoms 
returned or became even worse compared to when they were not medicated.[56] In Portugal 
and Spain, acceptability of generic medicines was based on whether the disease condition 
was serious or minor[57] – a similar finding to that observed in SA.[6,49] Consumers in 
Germany displayed a general scepticism because of the lower price and consumers in 
Norway generally did not perceive the generics to be equivalent to the IP and hence did not 
trust them.[48] 
2.6 Healthcare professionals’ acceptance of generic medicines 
The particular healthcare professionals referred to here are prescribers and dispensers. How 
prescribers and dispensers view generic medicines has an impact on the use of generics. It 
clearly influences prescribers’ prescriptions and dispensers’ substitution practices. They play 
a key role in promoting awareness of the use of generic medicines. Promotion of generics use 
by either the prescriber (doctor) or the dispenser (pharmacist) results in a greater acceptability 
of generic medicines.[6,48,49] 
A third of New Zealand pharmacists in one study were unable to correctly define the term 
generic medicine. This study exposed that the pharmacists also thought that generic 
medicines were of an inferior quality compared to the branded products. The pharmacists 
echoed the lack of trust displayed by some consumers as they had had to deal with patients 
                                                             
6  People’s Pharmacy www.peoplespharmacy.com  
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experiencing ADRs after a generic medicine had been substituted for a brand medicine.[41] 
Clinicians from the Allergy Society of South Africa (ALLSA) and the National Osteoporosis 
Foundation of South Africa (NOFSA) have suggested that clinical trials be done to prove 
interchangeability between generics and brand name drugs.[58] In a Finnish study half the 
doctors involved expressed that not all interchangeable / generic medicines are safe.[47] A 
national survey in Malaysia identified a lack of confidence in substitution of branded 
products. It showed that pharmacists were more willing to make generic substitutions for 
mild to moderately serious diseases and not serious diseases.[59] Some cardiologists and 
neurologists in the USA expressed concern over generics as any slight changes could have 
potentially serious negative effects on the patients’ health.[56]  
The automatic generic substitution system that the Department of Health of the UK 
considered introducing in 2009 was criticised for possible clinical implications for patients. It 
was highlighted that generic substitution may have a negative impact on adherence, 
particularly for patients on chronic medication. Elderly patients often develop routines based 
on the appearance of their medication. Any changes can be confusing. The potential to 
disrupt patients’ medication regimens, the potential for adverse reactions, and under-
treatment in other individuals were all mentioned as reasons why generic substitution may 
not be ideal.[50] 
2.7 The registration of generic medicines 
The WHO states that all pharmaceutical products including multi-source products should 
only be used in a country after approval by its local authority.[20] For countries that do not 
have functional regulatory bodies, the WHO guidelines are often adopted for use.  
2.7.1 Basis for registration 
For a generic medicine to be registered and put onto the market it has to show that it is of the 
same and appropriate standards of quality, safety and efficacy as the IP. Furthermore, 
reasonable assurance needs to be given that the generic is therapeutically equivalent and 
interchangeable with the IP.[18,20,22] This means that the generic medicine and IP contain 
the same amount of active substance, in the same dosage form, are intended for the same 
route of administration in the same molar dose and the effects they produce with respect to 
both efficacy and safety are essentially the same. The generic can therefore be interchanged 
with the IP in clinical practice.[18,20] The regulatory authority would be responsible for 
ensuring that products that get onto the market have met the appropriate standards.[1] 
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2.7.2 Interchangeability 
Interchangeability is the basic concept that is used in generic substitution,[60] when one 
product can be used in the place of another and the same results can be expected. Ideally the 
one product would be the IP and the generic is registered by using the IP as a comparator. 
The two products are meant to mirror each other in therapeutic effect and efficacy, quality 
and safety.[22] Figure 2.2 below indicates the concept of generic substitution and 
interchangeability. The double-sided arrows in the figure below indicate interchangeability. 
 
 
 
 
 
 
 
 
 
Figure 2.2: The concept of interchangeability7 
2.8 The Medicines Control Council 
The MCC is a statutory body established in terms of the Medicines and Related Substances 
Act, Act 101 of 1965.[61] The mandate of the MCC is to safeguard and protect the public 
through ensuring that all medicines that are sold and used in SA are, therapeutically effective, 
safe, and consistently meet acceptable standards of quality.[13,61] Companies apply to the 
MCC for registration of new products including multi-source medicines. The MCC requires 
applicants to show adequate evidence of safety, efficacy and quality. To facilitate this the 
MCC has prepared guidelines which are accessible from their website (www.mccza.com) to 
assist applicants in submitting appropriate data for registration.[62] Prior to the provision of 
these guidelines, the Registrar of Medicines used to publish circulars that were distributed to 
the stakeholders, and before that the Registrar and industry referred to what was commonly 
known as the ‘blue book’ which served as a common reference.[62] 
                                                             
7  Adapted from: http://www.saudiannals.net/text.asp?2008/28/1/33/51758 [Accessed 2011 Dec 7] 
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2.9 Tests used in proving equivalence with the innovator product 
There are in vivo and in vitro requirements that can be used to assure interchangeability of the 
generic medicine without compromising safety, efficacy and the quality of the 
pharmaceutical product.[63] While for some pharmaceuticals like parenteral formulations of 
high water content, Good Manufacturing Practice (GMP) and evidence of compliance with 
Pharmacopoeial specifications is sufficient to prove interchangeability, this is not the case for 
other dosage forms such as solid and liquid oral dosage forms. For these, more complex 
considerations would have to be made.[63] When the IP is registered it has gone through a 
long series of tests in animals and eventually clinical trials in humans.[18,28] Ideally, clinical 
studies would be performed to demonstrate whether or not there is equivalence between the 
IP and the proposed generic. This however requires a large number of participants and is 
financially daunting for the company wanting to register the generic. Therefore, when generic 
medicines are registered, clinical trials are not carried out. This not only conserves finances 
but also saves time.[18,25,58,63]  
2.9.1 Bioequivalence studies 
Biostudies or bioequivalence studies have been an accepted standard in ensuring the 
therapeutic performance of medicines following manufacturing changes as well as for generic 
medicines approval.[18,64] Bioequivalence means that there is absence of a significant 
difference in the rate and extent to which the active ingredient or active moiety in two 
pharmaceutically equivalent products becomes available at the site of drug action when 
administered at the same molar dose under similar conditions in an appropriately designed 
study.[63] The objective of bioequivalence testing is to quantify and thereafter compare the 
pharmaceutical performance of different formulations which are pharmaceutically 
equivalent.[62] The development of bioequivalence testing over the last 40 years has been 
critical to determining pharmaceutical and therapeutic equivalence. Experts in the science of 
bioequivalence testing, state that therapeutic equivalence can be assured when the 
multisource product is both pharmaceutically equivalent and bioequivalent, in which case it 
would be an alternative to the IP.[20] The WHO defines therapeutic equivalence as when two 
pharmaceutical products are pharmaceutically equivalent (or are pharmaceutical alternatives) 
and after administration in the same molar dose, their effects, with respect to both efficacy 
and safety, are essentially the same, if administered to patients by the same route under the 
conditions specified in the labelling.[20] Pharmaceutical equivalents are products that contain 
the same molar amount of the same API, in the same dosage form, if they meet comparable 
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standards, and if they are intended for administration by the same route.[20] Products are 
pharmaceutical alternative(s) if they contain the same molar amount of the same API but 
differ in dosage form (e.g. tablets versus capsules), and/or chemical form (e.g. different salts, 
different esters).[20] In South Africa the concept of pharmaceutical alternatives was first 
officially introduced in draft Regulations to the Medicines Act in July 2011. These 
Regulations have not yet been finalised. 
 
In vivo bioequivalence studies are done in healthy individuals representative of the general 
population in terms of age, sex and race. Usually ten or twelve participants are required for 
immediate release preparations and twenty for modified release preparations.[9,65] These 
studies measure the bioavailability of the test product and the reference product. The 
parameters analysed are maximum drug concentration (Cmax) and area under the curve 
(AUC). Figure 2.3 below indicates these two parameters. Blood samples are taken from the 
participants prior to taking the medicine. Further samples are taken at set time intervals after 
the medicine has been administered to determine the drug concentrations over time. A 
concentration vs. time profile can be constructed which will show the absorption, distribution 
and elimination of the drug. This profile also indicates Cmax and AUC.[18,62,63] 
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Figure 2.3: A concentration-time profile constructed from bioavailability studies8 
 
Bioequivalence standards are based on the test and reference products producing the same 
plasma concentration-time profiles.[64] Bioavailability can be defined as the rate and extent 
to which the API becomes present at the site of action.[20] There are three types of 
bioequivalence studies. These are: 
 
I. Fasting and single dose studies 
II. Fed and single dose studies and 
III. Fed and multi dose studies.[18] 
 
For the registration of generic medicines, at least the fasting and single dose study is 
required.[18] Bioequivalence can therefore also be defined as when two pharmaceutical 
products have bioavailabilities that are essentially the same in terms of peak Cmax, Tmax and 
AUC after administration of the same dose under the same conditions.[65] In general, 
bioequivalence studies for modified release preparations may require testing in both fed and 
fasting states. This is to demonstrate the effect of food and therefore exclude the possibility of 
dose dumping.[65] 
 
 
 
 
 
 
                                                             
8   This diagram is adapted from http://www.medscape.com/viewarticle/556234_4 MEC = minimum 
effective concentration; MTC = maximum therapeutic concentration 
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2.9.2 Dissolution studies 
Dissolution research has being progressing for over 100 years. It began as a field in physical 
chemistry and has developed from there to applications in the pharmaceutical industry.[66] 
The process of dissolution aids in the physiological availability of the drug. In vitro 
dissolution testing is also used and may give sufficient evidence that there is equivalence 
between a proposed medicine and a reference product.[9,20,67] In pharmaceutical terms 
dissolution can be defined as the rate of mass transfer from a solid surface into the dissolution 
medium or solvent under standardized conditions of liquid/solid interface, temperature and 
solvent composition.[68] Dissolution testing is an important tool used in drug development 
and in the quality control of medicines.[63,66] Dissolution testing was initially developed as 
a quality control tool to ensure batch to batch reproducibility.[54,66,68,70] In a dissolution 
experiment, the volume of the dissolution medium is fixed and the agitation is provided by 
either of two devices, a rotating mesh basket, or a rotating paddle, USP I and II 
respectively.[63] The rate of rotation, volume of medium and temperature are parameters that 
are kept constant so that the analysis indicates purely drug release from the dosage form into 
the medium. Analysis of the dissolution medium is done as it is collected at set time intervals 
and a dissolution profile is constructed.[65,67] To mimic in vivo conditions, dissolution 
testing can be repeated by varying the pH of the dissolution media; acidic to more basic, pH 
0.1, 4.5 and 6.8 (similar to the stomach and the small intestines). This gives an idea of drug 
release when the dosage form reaches those areas of the body.[65,67] 
Figure 2.4 is an example of a dissolution profile. The y axis shows the percentage of the drug 
released and this is plotted against time on the x axis. 
 
Figure 2.4: A dissolution profile for tablets in various pH9 
 
                                                             
9  Diagram source: This diagram is adapted from the one provided at: 
http://www.scielo.br/scielo.php?pid=S0100-40422007000500031&script=sci_arttext  
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While figure 2.4 depicts a dissolution profile for one product in different pH media, 
dissolution profiles used in bioequivalence studies would compare the test and reference 
products. The dissolution profiles of the test and reference products are tested for similarities 
using the f2 similarity factor10. An f2 value of greater than or equal to fifty indicates that the 
two dissolution profiles are similar and that there is no need for further in vivo studies. An f2 
value less than fifty indicates insufficient similarity and in vivo studies would be required. 
The exception to that general rule is when in both the test and reference products 85% or 
more of the API dissolves in less than fifteen minutes. In such a case, the similarity would be 
accepted without need for calculation of the f2 value.[67] 
In general the applications for dissolution testing include evaluation and approval of scale-up 
and post approval changes (SUPAC) of registered medicines. The evaluation of 
proportionally similar dosage forms and in vitro testing for biowaivers is based on the 
Biopharmaceutics classification system (BCS).[65,66] Other studies have however indicated 
that similar dissolution profiles may be obtained for bio-inequivalent products. Dissolution 
testing is not a reliable prognostic tool of oral drug absorption (from the gastrointestinal tract 
into the blood stream) because a viable link has not yet been established between drug release 
from a formulation (or various formulations) and drug absorption.[66] 
 
2.9.2.1 Scale-up and post approval changes 
After the registration of a medicine changes may be made in the manufacturing procedure or 
equipment, the site of manufacture and/or even the formulation. It is important to assess the 
effect of these changes on the quality, efficacy and safety of the products. Dissolution studies 
may be used under the specific conditions as a ‘surrogate’ method in assessing the impact of 
such changes.[67,71] The changes made to the registered pharmaceutical products are 
classified as either minor or major and designated as case A, B or C depending on the 
severity of the changes. The acceptance criteria applied to each case for the dissolution tests 
will differ.[18,67]  
 
2.9.2.2 Proportionally similar dosage forms 
Dissolution testing may be used when two dosage forms are proportionally similar and the 
higher strength of the dosage form has already been approved.[65] A lower strength of the 
dosage form may be approved based on dissolution testing if the constituents of the dosage 
                                                             
10  The similarity factor (f2) is a logarithmic reciprocal square root transformation of the sum of squared 
errors, and is a measurement of the similarity in the percentage (%) dissolution between the two curves. 
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form i.e. the API and excipients are proportional. The manufacturer of the dosage forms and 
the site of manufacture must also be the same. An appropriate bioequivalence study should 
have been done on at least one of the dosage forms, preferably the higher strength.[65,67] For 
example, waivers of in vivo studies may apply to lower strength beaded capsules when the 
strength differs in the number of beads containing the API.[65] 
 
2.9.2.3 The Biopharmaceutics Classification System 
The BCS is a scientific framework that classifies drug substances based on their aqueous 
solubility and intestinal permeability.[71,72] These two variables govern drug absorption.[64] 
The BCS was applied in practice by the introduction of waivers for in vivo bioequivalence 
studies/testing, and replacing these with comparative in vitro testing. The principle in the 
application of BCS is that if two similar medicinal products yield the same concentration 
profiles within the gastrointestinal tract following oral administration, they will lead to the 
same plasma profiles. Currently the MCC, FDA, EMA and WHO all refer to the BCS in their 
guidelines.[20,71,73] 
 
The BCS classifies APIs into four categories: 
• Class 1: High solubility and high permeability  
• Class 2: Low solubility and high permeability  
• Class 3: High solubility and low permeability  
• Class 4:Low solubility and low permeability  
Table 2.1: Examples of APIs in the BCS classes 
Class 1 Class 2 Class 3 Class 4 
Chloroquine Carbamazepine Acyclovir Taxol 
Diltiazem Danazol Atenolol Saquinavir 
Metoprolol Glibenclamide Captopril Ritonavir 
Paracetamol Ketoconazole Cimetidine  Furosemide 
Propanolol Nifedipine Metformin Ellagic acid 
Theophylline Phenytoin Neomycin B Cyclosporin A 
Verapamil Troglitazone Ranitidine Coenzyme Q10 
 
Class I APIs that are rapidly dissolving qualify for registration based on biowaivers and 
currently some class III products are also being assessed for inclusion into the group of APIs 
that can be exempted from in vivo bioequivalence studies.[64,72] The use of dissolution 
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testing assists in speeding up the process for drug approval and it is cheaper as compared to 
in vivo bioequivalence studies.[72] 
 
2.10 Reference products 
The tests used for the registration of generic medicines are all comparative. The product 
whose registration is being considered is tested against a reference product. The reference 
product is the one that the generic product is intended to be interchangeable with in clinical 
practice.[20] A reference product or comparator is a product that has been approved and has 
had its safety, efficacy and quality already established based on clinical trials. It is used as a 
standard against which the new product will be tested in either in vivo bioequivalence studies 
or in vitro comparative dissolution tests.[62] The suitability of a reference product is 
determined by the local drug or medicine regulatory authority.[20] The FDA compiled a list 
of comparators from which applicants can identify a reference product.[18] The WHO also 
has a list of comparators.[9] 
 
2.10.1 The domestic reference product 
The reference product used as a comparator in these studies would ideally be the domestic 
reference product (DRP) or a local IP.[62,63] A product that was developed and is 
manufactured locally, having had its registration dossier submitted within the country in 
which the multisource product wishes to be registered would be a suitable DRP.[63] 
 
2.10.2 The foreign reference product 
If the reference product is procured from another country it is called a foreign reference 
product (FRP). The Pharmaceutical and Analytical guideline of the MCC permits the use of 
FRPs.[9] There is no guarantee that the FRP’s quality, safety and efficacy have been 
established through clinical trials. The information that is required to be furnished when a 
FRP is used for purposes of registration includes:  
• The name and address of the manufacturer of the FRP  
• The qualitative formulation of the FRP 
• Copies of the immediate container label as well the carton or outer label of the FRP 
• For modified release, evidence of the mechanism of modified release of the FRP 
• The method of manufacture of the FRP if claimed by the applicant to be the same [as 
for the DRP] 
• Procurement information of the FRP.[9] 
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2.11 Changes in MCC guidelines regarding use of reference products and tests used in 
establishing equivalence over the years  
The sources of information used in this section include the ‘blue book’ (circa 1985 – used by 
the Registrars of Medicine and the Pharmaceutical Industry), circulars 14/89 of 1989 and 
14/95 of 1995 and the MCC guidelines available on the website dated June 2007 and June 
2011.  
2.11.1 The blue book 
The ‘blue book’ is in fact a file (with a blue cover) with the title: ‘Guide to Medicine 
Legislation’. It was published by the Pharmaceutical and Chemical Manufacturers 
Association of South Africa – which no longer exists. The copy referred to in this study was 
obtained from a former Registrar of Medicines. 
It contains the Medicines Act, its Regulations, certain MCC decisions, a marketing code and 
the Advertising Standards Authority’s Code of Advertising Practice. 
Chapter 5 of the ‘blue book’ outlines the requirements for registration of generic medicines.  
2.11.1.1 Tests involved in proving equivalence 
The blue book uses the term ‘pharmaceutical availability’ to refer to the in vitro 
determination of efficacy and this is established through the use of comparative in vitro 
dissolution studies performed on a minimum of five specimens of the dosage form and if 
possible, the active raw materials in question. These dissolution studies were designated for 
single active ingredient formulations and were not intended for formulations with special 
release characteristics.[74] Comparative in vivo bioavailability studies were required in 
proving the efficacy of formulations with any special release properties e.g. sustained release 
preparations and combination formulations, both solid and liquid dosage forms unless 
specifically exempted. The Council could also require the provision of clinical data in 
addition to the bioavailability studies.[74]  
2.11.1.2 Choice of a reference product 
The blue book makes a very bold and clear statement regarding the choice of a reference 
product:  
‘The innovator’s medicine will be the only standard against which pharmaceutical availability 
and bio-availability studies will be measured. If the innovator’s medicine is unregistered and 
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significant differences are found, the Clinical committee will be approached for an 
option.’[74] 
It then states that when identifying the reference products, the formulation needs to be similar 
and the product should already be registered in terms of the Medicines Control Act. (The 
Medicines Act was previously known as The Medicines and Related Substances Control 
Act.) In the event that a product with a similar formulation is not registered, a product 
acceptable to the Council could be used.[74] 
2.11.2 Circular 14/89 
Circular 14/89 was released on the 31st of December in 1989. The aim of the circular was to 
make stakeholders aware of how the policy had been modified about the required information 
and supportive data to be used as evidence of medicines efficacy when applying for 
registration. It superseded circular 4/86 and 1/88 which had related information.  
2.11.2.1 Tests involved in proving equivalence 
In Circular 14/89, dissolution testing as a means of proving efficacy is mentioned as being 
suitable only for products that have the dissolution requirement included in the USP for 
single active ingredients or for a combination of active ingredients. In the event that the 
Council did not have any queries, such products’ pharmaceutical availability data was 
sufficient in support of efficacy. The circular also states that pharmaceutical availability data 
may be submitted for vitamin and mineral combinations and multivitamins as long as the 
dissolution rate of the least water soluble vitamin plus one other vitamin was determined.[75] 
A list of active ingredients that required tests other than comparative dissolution studies was 
attached to the circular. See Appendix 1. 
Comparative bioavailability studies are mentioned as a requirement for the assessment of 
efficacy for antibiotic and antibiotic combinations. Regarding general tablets, capsules, 
suspensions and suppositories, guidelines regarding bioavailability studies are given i.e. the 
number of subjects to be involved in the study.  
‘If bio-availability data are submitted for efficacy evaluation, at least ten experimental 
subjects are required in a crossover design and 20 subjects for long acting (slow release) 
preparations…’[75]  
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2.11.2.2 Choice of reference product 
Again in Circular 14/89 the MCC boldly and clearly states that the reference product to be 
used in these comparative studies has to be the IP: 
‘The Innovator’s product will be the only standard against which pharmaceutical availability 
and bioavailability studies shall be measures, whether the Innovator’s product is registered or 
not, the only exception being multivitamins and vitamin and mineral combinations…’[75] 
2.11.3 Circular 14/95 
This circular was distributed on the 10th of February, 1995 titled ‘Data required as evidence 
of efficacy in annexure 13’. It replaced circular 10/91. The circular deals with generic 
medicines and tests involved in proving efficacy. 
2.11.3.1 Tests involved in proving equivalence 
In Circular 14/95 eight options of tests are listed for use in proving efficacy depending on the 
relevance of the tests. These are, in order of appearance in the circular:  
• Bioavailability 
• Dissolution 
• Disintegration 
• Acid neutralising capacity 
• Microbial growth inhibition zones 
• Proof of release by membrane diffusion 
• Particle size distribution 
• Blanching test and  
• any other method an applicant wishes to submit provided the rationale for submitting 
the particular method is included.[76] 
 
When the circular discusses bioavailability studies, it lists instances in which bioavailability 
studies must be done as proof of efficacy for registration. One of those is when a modified 
release preparation or capsule e.g. slow and sustained release dosage form is being tested.[76] 
The circular further discusses when dissolution tests can be used as proof of efficacy. The 
information given is similar to circular 14/89, the active has to have a USP requirement and 
the active should not appear on the list of attached active ingredients which required more 
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tests besides comparative dissolution studies. No other exceptions to dissolution testing are 
made besides the active ingredients listed and attached to the circular11.[76] 
2.11.3.2 Choice of reference product 
For a generic medicine, the choice of a comparator or a reference product to be used in 
comparative studies to prove efficacy must be a well-established innovator product. The 
choice of the IP must be justified by the applicant. In the case where the applicant seeks to 
register a product with different formulations, the product has to be compared with the 
product that was used in the clinical trial. In instances where there are major changes that 
have been done to the product that is being applied for, the product that was on the market 
prior to the changes was to be used as the reference.[76] 
2.11.4 June 2007 MCC guidelines 
The 2007 MCC guidelines referred to are the Pharmaceutical and Analytical, Dissolution and 
Biostudies. These documents were intended to be guidance for industry. The Pharmaceutical 
and Analytical guideline is an umbrella guideline for the quality of medicines. The 
Dissolution guideline describes how to conduct dissolution testing and the settings and 
specifications under which dissolution testing may be used as a quality control requirement 
and in support of a waiver for bioequivalence testing. The Biostudies guideline defines 
bioavailability and bioequivalence and explains when they will be required in order to prove 
safety and efficacy. Guidance is provided on how to conduct the appropriate studies and how 
the data acquired are to be evaluated. This guideline also indicates when in vitro instead of in 
vivo studies may be used.[77-79] 
2.11.4.1 Proof of efficacy 
A similar list to that provided in circular 14/95 is given in the Pharmaceutical and Analytical 
guideline showing the available methods for proving equivalence and again, all the tests are 
meant to be comparative.[77] The Dissolution guideline describes dissolution as both a 
quality control requirement and as a ‘surrogate’ to bioavailability studies. The term bio-
waiver is described, which depicts a scenario were in vivo bioavailability studies are waived 
and dissolution studies used to prove equivalence. Bio-waivers are only applicable if the 
active substance is highly soluble and should not cause any bio-availability problems.  
                                                             
11  Appendix 1 
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In addition to that, the active substance must be in a dosage form that is rapidly dissolved in 
the physiological pH interval after administration.[78,79] 
Bio-waivers are also permissible when different strengths of a registered product are being 
introduced.[65] The Biostudies guideline states that in vivo bioequivalence studies through 
pharmacokinetic bioavailability, pharmacodynamic studies or a comparative clinical trial are 
especially important when dealing with drugs where there is a risk of possible differences in 
bio-availability which may result in therapeutic inequivalence. An example given is in the 
registration of modified release pharmaceuticals designed to act by systemic absorption.[79] 
2.11.4.2 Reference products 
In 2007 the MCC recommended that the reference product should preferably be a locally 
procured product. In the event that there is more than one product that qualifies as a reference 
product, the market leader should be used as long as proof was provided of market 
leadership. The Pharmaceutical and Analytical guideline goes on to give four options 
regarding reference products, in order of preference:  
(i) the innovator product registered and procured in South Africa; or 
(ii) the innovator product for which a marketing authorization has been granted by the 
health authority of a country with which Council aligns itself (see General 
Information guideline 3.1.4), and which is to be purchased from that market, or 
(iii) a product from the latest edition of the WHO International comparator products for 
equivalent assessment of interchangeable multisource (generic) products QAS/05.143.  
[http://www.who.int/medicines/services/expertcommittees/pharmprep/QAS05_143_C
omparator] The primary manufacturing site is indicated in the WHO comparator list, 
and the comparator is to be purchased in that country, or; 
(iv) in the case that no innovator product can be identified – within the context of (i)–(iii) 
above, the choice of the reference must be made carefully and must be 
comprehensively justified by the applicant.[77] 
A note is given below this list: 
 ‘...a product that is approved based on comparison with a non-domestic reference product 
may or may not be interchangeable with currently marketed domestic products.’[77] 
The choice of the reference product also needs to be justified by the applicant and details 
regarding the country from where it is procured are to be provided.[77]  
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2.11.5 June 2011 MCC guidelines 
The June 2011 guidelines are mostly similar to the June 2007 guidelines. Additional 
information is given in the Biostudies guideline about the requirements needed if a foreign 
reference product is used as the comparator.[65] 
The guidelines inform applicants that the choice of reference product can be made by the 
applicant and a sufficient justification must be provided. The provision for use of a foreign 
reference product is made. This may be a product registered in South Africa but procured in a 
country with which the MCC aligns itself with.[9] 
Table 2.2 below is a summary of the changes over time in reference product choice and tests 
required to prove equivalence derived from the MCC documents referred to. 
Table 2.2: Changes in the MCC guidelines over the years 
 Blue book Circular 14/89 Circular 
14/95 
June 2007 June 2011 
Tests to 
prove 
equivalence 
Bioavailability 
studies for all 
modified release. 
Dissolution for 
single active 
ingredient 
preparations only 
Bioavailability 
studies for all 
modified release. 
Dissolution 
accepted for 
combination 
ingredients. List 
of exceptions 
Bioavailability 
studies for all 
modified 
release.   
Dissolution 
can be used 
except for 
listed 
exceptions 
Bioavailability 
studies for all 
modified 
release except 
when bio-
waiver applies 
Bioavailability 
studies for all 
modified 
release except 
when bio-
waiver applies 
Choice of 
reference 
product 
Only Innovator 
product 
Only Innovator 
product 
Innovator 
product and 
choice to be 
justified 
Four choices 
including FRP 
Four choices, 
including FRP 
 
2.12 Controversies surrounding the use of generic medicines 
There are various controversies about the use of generic medicines. Concerns, views and 
perspectives raised by consumers and healthcare professionals have already been mentioned. 
The following issues are raised by academics, scientists and researchers. They look at generic 
medicines from a more scientific and pharmaceutical perspective. 
 
 
 29 
2.12.1 Differences in content 
As much as the generic medicine contains the same API as the IP, the chemical form may be 
different i.e. another salt or ester of the API. Two different salts of the same compound may 
not be identical and may exhibit different solubilities and absorption characteristics. This 
becomes problematic as dosages may often be expressed as the weight of the salt rather than 
the weight of the actual API.[51] Besides that, though the salts may be tested and proven to 
be bioequivalent, therapeutic equivalence also refers to the same safety and efficacy. When 
different salts or esters are used the stability and toxicity of the products may change.[80] 
Polymorphism is also a concern when it comes to the API. Quality release and stability 
testing can become problematic as a result of a change in polymorphic forms of the API. For 
example, Norvir®, which is a brand of semi-solid ritonavir in capsules, went onto the market 
in 1996 and in 1998 the drug began to precipitate in the capsule. The form I of the drug had 
converted to form II.[81] As polymorphism affects dissolution and drug absorption in the 
gastro intestinal tract, it is important to ensure the manufacturing and storage procedures 
maintain the desired polymorph.[80,81]  
 
Mebendazole, which is a widely used anti-helminthic has three polymorphs, A, B and C the 
preferred being C. In 2002 a study on the ability of dissolution testing to distinguish between 
the different polymorphs was done and one of the conclusions made was that it was critical 
for importers of Mebendazole to import the correct polymorph as various generics were on 
the market. They also identified that the removal of sodium lauryl sulphate from the 
dissolution medium was one method of identifying between the polymorphs.[82] 
 
In terms of content, the excipients used i.e. stabilising, bulking, sweetening, colouring and 
flavouring agents may also vary between products. This could possibly provoke not only 
allergies or intolerance but also result in serious adverse drug reactions.[29,51] In 2007, 
GlaxoSmithKline (GSK) introduced a new formulation of levothyroxine which contained 
different excipients compared to the originator product onto the market. The new product 
caused weight gain, lethargy and visual disturbances and in just over a year, 746 adverse 
reactions had been reported in New Zealand alone.[41] 
 
2.12.2 A normal and healthy population 
In vivo bioequivalence studies are performed in a ‘normal and healthy’ population.[20,73] 
The assumption that, if bioequivalence is exhibited in a normal and healthy population this 
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will equate to comparable tolerability and clinical efficacy in a patient (i.e. sick) population, 
has not been established as fact.[50,83] 
  
2.12.3 Inter-ethnic variability 
 
Due to genetic polymorphism in individuals’ drug-metabolizing enzymes, there is a high 
degree of variability in drug metabolism among populations.[73,84] Differences in ethnic 
groups may result in significant differences in the ability to metabolise certain drugs.[84-87] 
The enzymes of the cytochrome P450 family play a key role in the metabolism of various 
drugs. Genetic variations among different ethnic groups result in genetic polymorphism and 
the same enzyme may be expressed differently in different ethnic groups.[84] The 
cytochrome (CYP) enzymes can have significant differences between the following 
subfamilies CYP2D6, CYP2C, CYP3A, CYP1A2 and CYP2A6 in Caucasians and East 
Asians.[84] 
 
CYP2D6 which metabolises generally lipophilic drugs has over 80 variants. A study done 
analysing the differences in the pharmacokinetics of certain drugs amongst East Asians and 
Caucasians indicated that the Asians required less neuroleptic medication compared to the 
Caucasians. The metabolism of codeine also shows significant differences between ethnic 
groups.[84] A product tested in and approved for a particular ethnic group may not perform 
equally well in a different ethnic group. Countries in the European Union (EU), Japan and the 
USA identified this as a problem.[88] Ethnic differences resulted in altered safety, efficacy, 
dosage and dosage regimens of drugs and this caused a reluctance to use foreign clinical data 
in the registration of drugs. To resolve this problem, the countries came together and drafted 
a set of guidelines that facilitated use of foreign data in an effort to minimise on the tests 
involved in drug approval.[84,88] This is how the ‘International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use’ (ICH) guidelines were developed.[88] In Africa similar efforts have been initiated to 
harmonise the pharmaceutical industry  and regulation in an effort to increase speedy access 
to medicines, improve public health and ensure provision of high quality and effective 
medicines for the treatment of priority diseases.[89,90] The harmonisation would also 
involve the development of uniform guidelines for use within the countries participating in 
the harmonisation and ultimately lead to cost saving benefits for these participant countries. 
[89,90] 
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2.12.4 Universal bioavailability limits 
There is a different understanding of the term bioequivalence from country to country. The 
Latin American countries; Bolivia, Columbia and Peru insist that bioequivalence testing 
involve clinical trials in human beings. They consider other tests such as dissolution testing 
and other in vitro testing insufficient to classify a product as a generic.[91] On the other hand 
Brazil and Argentina register a product as a generic if it has the same active ingredient as the 
IP, regardless of the tests done to prove bioequivalence.[91] The parameters assessed in 
bioequivalence studies are AUC and Cmax. Limits are set for these two parameters at a 90% 
confidence interval. In SA the limits for AUC are 0.8 to 1.25 and for Cmax it’s 0.75 to 1.33. 
These limits are consistent with those of most countries, for example Canada, USA and 
Australia, except that the Cmax values in SA are wider than the 0.8 – 1.25 set for those 
countries.[63] Table 2.3 below shows AUC and Cmax values from different countries and 
those recommended by the WHO. 
 
Table 2.3 Limits for Cmax and AUC in various countries 
Country  Limits for AUC  CI Limits for C max  
USA  0.8-1.25  90% 0.8-1.25 
Canada  0.8-1.25  90% 0.8-1.25 
Europe  0.8-1.25  90% 0.8-1.25 
 HVDs 0.8-1.25  90% 0.8-1.25 
Australia  0.8-1.25  90% 0.8-1.25 
 HVDs 0.75-1.33  90% 0.8-1.25 
WHO  0.8-1.25  90% 0.8-1.25 
India  0.8-1.25  90% 0.8-1.25 
South Africa  0.8-1.25  90% 0.75-1.33 
 HVDs scaled 0.80-1.25  90% Scaled 0.75-1.33 
 HVDs 0.70-1.43  90% 0.8-1.25 
 
HVDs are highly variable drugs. These are drugs where the within-subject % coefficient of 
variation (%CV) of Cmax and/or AUC is greater than 30%. The wider limits for Cmax in SA 
were due to a special dispensation due to some unspecified difficulty in identifying 
Cmax.[63] 
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2.12.5 Lack of equivalence 
Various reports regarding the lack of equivalence of the generic medicines to the IP have 
been made. An independent laboratory in the USA testing the equivalence of an original 
product of budeprion vs. the generic version showed different dissolution rates.[56] 
Budeprion is an antidepressant available as a modified release preparation.[92]  
The generic version released the drug at a significantly faster rate than the IP, which may 
have accounted for the various side effects people had been reporting.[56]  
Nifedipine is an anti-hypertensive drug which is also used in the treatment of chest pain due 
to coronary artery spasm. It is available under the names Adalat®, Nifedical® and 
Procardia®. In 2008, the NAPM complained to the Advertising Standards Authority (ASA) 
as questions had been raised regarding the equivalence of generic nifedipine to the IP. At 
least two of the generics that had been tested had failed to prove bioequivalence. The NAPM 
complained that there had been a misinterpretation of facts and that the studies done were not 
relevant to the SA market as they related to testing in Europe for a European market. The 
ASA dismissed the complaint as Bayer, the manufacturer responded by stating that no 
information was available in SA regarding nifedipine and hence facts from Europe had been 
used.[93] It must be noted that the ASA dealt only with the advertising claims made for these 
products as it does not have the regulatory authority to rule on the correctness of the 
registration of medicines. 
Anti-seizure drugs are particularly problematic in the area of generic substitution. Some 
healthcare professionals argue that generic anti-epileptics are not equivalent to the brand 
name agents.[83,94] A survey of over three hundred neurologists indicated that 169 of 289 
respondents reported breakthrough seizures in their patients with generics; and 163 of 291 
reported an increase in adverse events on switching to a generic anti-seizure agent. 
Substitution of agents with narrow therapeutic ranges was identified as problematic; 
phenytoin, in particular, not only has a narrow therapeutic index, but also displays non-linear 
pharmacokinetics.[83]  
2.13 The Promotion of Access to Information Act 
South Africa and Zimbabwe were the first two countries in Southern Africa recognised to 
have legislature regarding access to information.[95] The Promotion of Access to Information 
Act, Act 2 of 2000 (PAIA) in South Africa was introduced in March 2001 and amended in 
February 2002.[96] 
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2.13.1 The purpose of PAIA 
The PAIA was introduced after it had been recognised that the system of government in SA 
prior to April 1994 had resulted in a secretive and unresponsive culture in both public and 
private bodies. The apartheid era was characterised by segregation, secrecy and oppression 
which often led to abuses of power and human rights violations.[96,97] After 1994, one of 
the goals of the new government was to be transparent and accountable in an effort to be 
regarded as credible by the people of South Africa. The right of access to information was 
included in the Bill of Rights within the Constitution of South Africa12. Section 32 protects 
the right of access to information as a fundamental right.[97,98]  
PAIA attempts to foster and encourage a culture of transparency in both public and private 
bodies. It serves to promote a culture in which the people of South Africa have the ability to 
gain access to information so they may fully exercise their rights.[95-97] To enable the 
people to do this the South African Human Rights Commission (SAHRC), a so-called 
‘Chapter 9 Institution’ created by statute in Chapter 9 of the Constitution, was given the 
mandate to compile simple and easily comprehensible guidelines on how to use the PAIA. 
The SAHRC was also to be responsible to ensure that state institutions and private bodies 
developed PAIA ‘manuals’ in accordance with Sections 10 and 51 of the Act, and that these 
manuals were available for public viewing.[96,98] The SAHRC also promotes the use of 
PAIA to the public in collaboration with organisations such as the South African History 
Archive (SAHA) and the Open Democracy Advice Centre (ODAC).[99] 
2.13.2 The challenges surrounding PAIA 
PAIA is regarded as an underused Act. Ordinary members of the public have been identified 
as being generally unaware of the PAIA and their right and ability through it to obtain access 
to information. A report by the National PAIA Civil Society Network indicates that although 
the use of the PAIA has been increasing, the substantial failure of information holders to 
respond has rendered the requests ‘futile’.[100] In a report compiled discussing the 
implementation of PAIA in the first ten years after its implementation, it was noted that many 
responses given to PAIA requests were blanket refusals with inadequate justification.[101] 
Officials in state institutions have also displayed a lack of awareness of the Act. This general 
lack of education and awareness surrounding the Act is a concern, and the ODAC, SAHRC 
and other organisations have made efforts to increase awareness by hosting workshops, 
                                                             
12  The constitution of the Republic of South Africa, 1996 (Act 108 of 1996). 
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conferences and distributing leaflets about the PAIA.[96,100,102] The National PAIA Civil 
Society Network (PAIA CSN) is a collaboration of individuals and organisations that 
promote PAIA, and work towards achieving the desired openness and accountability that the 
Act represents.[99] 
Another challenge regarding the full implementation of PAIA is the procedure involved in 
resolving disputes that may arise in the event that a request for information is denied.[102] 
An Internal Appeal process is available for public institutions. In this a requester may ask for 
a decision regarding a refusal to a request to be reconsidered. In the event that a request is 
denied after an internal appeal the matter would have to be taken to court.[96] In private 
institutions, there is no internal appeal structure and the only recourse available to a requester 
in the event of a refusal is to approach the courts.[96] Due to the expense and cumbersome 
nature of arranging court cases, implementation of the Act may be compromised.[102] 
Initially, PAIA cases were dealt with primarily in the High Court. In an effort to increase the 
enforcement of the Act, Magistrates are being trained in its use. Poor records management 
also presents a challenge as records were found to be not easily accessible.[100] The 
challenges of course do not compare to what was probably the greatest of them all: the 
breaking of the secretive culture that had developed during apartheid. Some attitudes and 
practices continue to manifest a lack of openness.[100] 
A pre-PAIA court case, Korf v Health Professions Council of South Africa highlighted how 
effective the PAIA might eventually be without having to resort to the courts. In this case, the 
applicant requested hospital files in order to institute legal action against a medical 
practitioner.[103] The request was made in terms of Section 32 of the Constitution13. It was 
denied by the hospital as the records had been passed on to the Health Professions Council of 
South Africa (HPCSA) for a disciplinary proceeding. The HPCSA refused access to the 
documents on the grounds that they were confidential. The court however decided in favour 
of the applicant.[103] 
2.13.3 PAIA in the private sector 
A private body is defined in the Promotion of Access to Information Act as: 
(a) a natural person who carries or has carried on any trade, business or profession, but only in 
such capacity; 
(b) a partnership which carries or has carried on any trade, business or profession; or 
(c) any former or existing juristic person, but excludes a public body.[97] 
 
                                                             
13  Access to Information clause 
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Section 51 of the PAIA indicates that the head of a private body must establish a PAIA 
manual within six months of establishment of the body: 
Manual 
51. (1)Within six months after the commencement of this section or the coming into existence 
of the private body concerned, the head of a private body must compile a manual 
containing— 
(a) the postal and street address, phone and fax number and, if available, electronic mail 
address of the head of the body; 
(b) a description of the guide referred to in section 10, if available, and how to obtain access 
to it; 
(c) the latest notice in terms of section 52(2), if any, regarding the categories of record of the 
body which are available without a person having to request access in terms of this Act; 
(d) a description of the records of the body which are available in accordance with any other 
legislation; 
(e) sufficient detail to facilitate a request for access to a record of the body, a description of 
the subjects on which the body holds records and the categories of records held on each 
subject; and 
(f) such other information as may be prescribed. 
(2) The head of a private body must on a regular basis update the manual referred to in 
subsection (1). 
(3) Each manual must be made available as prescribed. 
(4) For security, administrative or financial reasons, the Minister may, on request or of his or 
her own accord, by notice in the Gazette, exempt any private body or category of private 
bodies from any provision of this section for such period as the Minister thinks fit.[97] 
 
When a request is made to a private body, the application must indicate that it is protecting or 
exercising a particular right.[97,102] It is argued that this requirement often discourages the 
public from using PAIA to request information from private bodies. The Companies Act of 
2008 is another statute which encourages accountability and transparency in the private 
sector.[102] 
2.13.4 PAIA in the Public sector 
Like private bodies, public bodies are required to have PAIA manuals. A public body is 
defined by the Act as: 
(a) any department of state or administration in the national or provincial sphere of 
government or any municipality in the local sphere of government; or 
(b) any other functionary or institution when— 
(i) exercising a power or performing a duty in terms of the Constitution or a provincial 
constitution; or 
(ii) exercising a public power or performing a public function in terms of any legislation.[97] 
 
A report compiled in 2007 indicated that only 40% of government institutions had developed 
the PAIA manuals.[100] In general obtaining information from public bodies is problematic. 
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Some public bodies do not have deputy information officers who are responsible for 
responding to the requests as mandated by the Act.[100] To add to that, a clear protocol may 
not be in place regarding the PAIA in public bodies, and often when a request is received 
there is a reluctance to furnish the information. Only 36% of government institutions had a 
system for handling information requests in 2007.[100] 
The PAIA CSN from 01 January to 31 July 2009 submitted various PAIA requests to public 
bodies at national, provincial and municipal levels. Only 12.7% of those requests received 
responses within the stipulated 30 days. At the end of the seven-month period, 34.5% of the 
requests had been responded to in full. For the remainder, the information was pending – 
either the decision of an internal appeal or litigation.[100]  
2.13.5 Transparency 
Transparency can be defined as ‘The condition of being transparent’, meaning having the 
capacity to allow light to shine through, being frank, open, candid and ingenuous. It 
encompasses being easily seen through, recognised, understood, obvious and clear.[104] The 
Business dictionary gives four definitions for transparency, one of which is: ‘An essential 
condition for a free and open exchange whereby the rules and reasons behind regulatory 
measures are fair and clear to all participants’.[105] Transparency means there is visibility into 
a company’s functions and activities for all stakeholders. The company would be 
acknowledging that its actions affect the stakeholder and transparency increases the 
stakeholders’ confidence in the company.[106] It leaves room for recommendations and in 
various way improves the performance of the business.[106] 
Transparency in the pharmaceutical context includes clinical trials and pricing and profits. In 
terms of clinical trials, various scandals have been reported in the pharmaceutical industry in 
the USA and European Union countries that resulted in a distrust of the industry by the 
public.[107-109] The fair and uniform disclosure of information is generally encouraged 
when clinical trials are done. Selective disclosure of information was reducing the credibility 
of pharmaceutical firms.[107,108] Methods have been developed by the EMA in an effort to 
allow the public to have access to otherwise confidential information. Representatives from 
patient and healthcare professional groups have been appointed as members of the 
management board of the EMA in an effort to empower the public. This level of transparency 
allows the public to know the reasoning behind certain decisions.[109] It also allows them to 
voice their opinions on policies and strategies regarding decision making around disease 
states. This allows for consistency and openness and the system in which ‘patients and HCPs 
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do not understand because someone else understands for them’ is abandoned. The EMA went 
as far as making assessment reports for the authorisation of new medicines available to the 
public.[109] 
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Chapter 3: Methodology 
 
3.0 Introduction 
The study is framed as a case report using an ‘Action Research’ methodology. This chapter 
elaborates on Action research and its use in data collection for the study. Due to the cyclic 
nature of the action research approach, certain aspects of the unfolding methodology are 
presented in the results section, chapter four.  
3.1 Action Research 
Action research was first defined by Kurt Lewin, a social psychologist. Lewin described a 
form of research that not only identified the problems but included mechanisms for 
addressing the problems.[110] Action research is a form of inquiry that enables practitioners 
to investigate and evaluate their work in an ongoing fashion. It has also become increasingly 
popular as a means of professional learning. Action research provides researchers a 
mechanism to conduct research from a more involved (participant) point of view as compared 
to the more commonly used ‘spectator’ approach.[111] Participatory action research (PAR), 
which is a branch of action research, has been used in healthcare to solve problems in 
communities, thereby making sound contributions to the mainstream healthcare arena and 
nursing practice.[112]  
Koch and Kralik believe that by working together with all stakeholders, participatory action 
research is a vehicle for making a difference in people’s lives.[112] This type of action 
research is said to raise consciousness, produce knowledge and implement actions which 
empower people. The aim of action research is to result in improvements after a problem has 
been identified. The improvements involve the participation of ‘practitioners’ and the ‘target’ 
communities specific to the situation. Various means are used to generate data in action 
research ranging from observation, interviews and participants’ written accounts.[110]  
The ‘spectator’ (observer) approach which is often adopted in social research asks questions 
like; What are those people over there doing? How can we understand and explain what they 
are doing? This usually occurs when an outsider is conducting the research. When an insider 
is doing the research, the questions differ and become: Is our work going well? How do we 
improve it where necessary? This form of insider research can be taken further to a highly 
individual and personalised level. The questions asked become What am I doing? What do I 
need to improve? How do I improve it?[111] Three words form the basis for action research: 
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‘Look, Think and Act’. In its cyclic nature, action research promotes reflection and 
reconstruction.[112] 
Action research often makes use of an action-reflection cycle shown as figure 3.1. The 
action-reflection cycle is a disciplined and systematic approach to research and the steps 
involved would often be: 
• To take stock of what is going on. 
In this study, determining the current situation about the registration of generic 
medicines in South Africa, and what’s been documented in literature.  
• Identification of a concern. 
The concern identified was the apparent use of FRPs to register generic medicines, 
possibly based only on comparative dissolution studies. Prescribers, dispensers and 
consumers are not informed about the comparators or tests used to register generic 
medicines. These concerns, and whether the ‘stakeholders’ should be informed, 
contributed to the research question.  
• Thinking of a possible way forward. 
The investigator considered means of an initial pilot determination of the use of FRPs 
and of the tests used to prove equivalence. A plan of action was devised. The use of 
the PAIA was identified as a instrument which could provide the information. 
• Trying it out. 
Requests were sent to the identified stakeholders. 
• Monitoring the action and gathering data.  
• Evaluating progress.  
Judgments about the validity of the data.  
• Modifying practice in the light of the evaluation. 
Repeating the cycle with changes if necessary. 
If an acceptable outcome is not achieved, the process would be modified and the cycle 
repeated until the results are deemed satisfactory. 
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Figure 3.1 Action-reflection cycle14 
3.2 Research Context 
‘Action research is a participatory, democratic process concerned with practical knowing in 
the pursuit of worthwhile human purposes . . . It seeks to bring together action and reflection, 
theory and practice, in participation with others, in the pursuit of practical solutions to issues 
of pressing concern to people and more generally the flourishing of individual persons and 
their societies’.[112] 
This statement highlights certain key aspects of action research displayed in this research. 
The investigator is a trained pharmacist and the research is within her scope of practice. It is 
linked to her profession from a pharmacovigilance15 perspective. The investigator took a 
stance of the MCC and pharmaceutical companies being partners in healthcare provision, 
along with prescribers, dispensers and other healthcare professionals who were not directly 
involved in the study. The key action research questions used for the study were: ‘Is our work 
going well? In particular, is the current method for the registration of generic medicines the 
best possible? If not, how do we improve it where necessary?’  
3.3. Case study format 
This research was carried out as a pilot study in a case study format. As a case study, it 
involves a process of research and recording of developments relating to a particular 
                                                             
14   Action-reflection cycle adapted from McNiff and Whitehead 2006[111] 
15  Pharmacovigilance is the science and activities relating to the detection, assessment, understanding, 
management and prevention of drug related adverse reactions and effects or any others possible drug-related 
problems. WHO. The Importance of Pharmacovigilance. 2002. 
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individual or small group or institution.[104] The definition of case study more specifically 
describing this study is: 
“…the collection and presentation of detailed information about a particular participant or 
small group, frequently including the accounts of subjects themselves…” [113] 
The emphasis in this study is exploration and description through use of the action research 
tool. 
3.4 Ethics clearance  
Prior to the collection of the data, the ethics committee in the Faculty of Pharmacy was 
approached to ascertain if formal ethics clearance was required for the research. As no 
humans or animals were involved in the study, the investigator was informed that ethics 
clearance would not be required and data collection commenced thereafter. 
3.5 Initial selection of generic products 
The sample size for the study was set at 20 generic products.  This was done to make the pilot 
study more manageable.  The 20 products were selected from the Generics Dictionary16. The 
20 products were selected using a random number generator (RNG)17 with no defined 
inclusion or exclusion criterion from all the products in the generics dictionary and products 
selected were allocated the numbers 1 – 20.  
Using a hypothetical example: simvastatin is selected as one of the active ingredients chosen 
for the study. The number of trade names and companies that manufacture similar simvastatin 
preparations, in terms of dosage strength and dosage are then selected as presented 
alphabetically in the dictionary and, excluding the innovator product, numbered from 1 to n 
(n being the total). The numbers from 1 to n are entered into the RNG, the trade name 
allocated to number 1 is selected, and the company for that brand is included in the study. 
The process is represented in figure 3.2 below. 
 
 
 
                                                             
16  Generics dictionary: a trade publication listing active pharmaceutical ingredients and the innovator and 
generic options available. It is used to promote the use of generic medicines. For every active ingredient, the 
trade names, their strengths, dosage forms, scheduling status, pack sizes, trade prices, single exit prices and 
other relevant prices were applicable. Volume 16 (1) Feb/March 2011 was used. 
17   An online random number generator was used: www.random.org/sequences/  
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Figure 3.2: The selection procedure of the products and companies  
The products selected represent a wide range of pharmacological classes. However, on 
evaluation of the initial sample, no modified release or Biopharmaceutics Classification 
System (BCS) class IV products18 had been included. As a result the process was repeated to 
include only such products. 
3. 6 Rationale for selection criteria 
It was decided to include only modified release and BCS class IV products after discussion 
with experts in the field. These are the generic products about which there are concerns 
related to registration procedures.  
3.6.1 Modified release preparations 
Modified release preparations are pharmaceutical preparations that do not exhibit immediate 
release properties.[9] According to the MCC Biostudies guideline, in vivo equivalence studies 
are required for modified release preparations designed to act by systemic absorption. In vivo 
                                                             
18  API’s that exhibit poor solubility and poor permeability 
Simvastatin 
Simvastatin 20mg TABS 
Choice of a particular 
strength (e.g. 20 mg) 
and dosage form (tabs) 
Select all trade 
names 
Exclude Innovator 
product 
17 different generics 
Random number 
generator 
Generic brand allocated to number 1 
(responsible company contacted for study) 
 43 
documentation of bioequivalence can either be through a pharmacokinetic bioequivalence 
study, a comparative pharmacodynamic study, or a comparative clinical trial.[65] 
3.6.2 BCS Class IV preparations 
BCS Class 1 APIs exhibit high solubility and high permeability. This class of APIs often 
qualify for waivers of in vivo bioavailability i.e. biowaivers, as they are characterised as 
rapidly dissolving.[9,64,72] Comparative dissolution studies may therefore be considered 
adequate to establish bioequivalence. However BCS Class IV APIs are not eligible for such 
waivers and require in vivo bioequivalence studies to establish equivalence.[65] 
3.7 Final sample selection 
The investigator identified and listed all the modified release products alphabetically by 
active ingredient provided more than two generics were included in the ‘Generics 
Dictionary’. A similar list was made for the BCS Class IV products. Twenty-three modified 
release products were identified, and those randomly assigned the numbers 1 – 19 were 
selected. Two BCS class IV products were identified and the product randomly assigned the 
number 1 was selected. 
3.7.1 Selection of companies 
Having selected 20 modified release and BCS Class IV generic medicines, the next stage was 
to identify which companies were responsible for these 20 medicines. For each generic 
medicine, a list of trade names in alphabetical order was provided by the generics dictionary. 
Each trade name was associated with the name of the company responsible for it. The 20 
medicines chosen were represented by nine pharmaceutical companies.  
To ensure exclusion of the IPs in the selection process, the cost of the products, as listed in 
the dictionary were used because the IPs were significantly more costly compared to generic 
medicines.  
3.8 Obtaining contact details 
In communicating with the respective companies and the Registrar of the MCC, the 
investigator chose electronic communication using e-mail. The PAIA stipulates that requests 
to private bodies are to be addressed to the Chief Executive Officers (CEOs) of the respective 
companies. Requests to public bodies are to be addressed to the Information officer. The 
email addresses of the CEOs of the nine companies were obtained from various sources. A 
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partial list of four CEO’s direct email addresses was obtained from a member of a 
pharmaceutical organisation. One email address was provided by an academic, but it was for 
the regulatory pharmacist of the company. The remaining four email addresses used were 
those provided by the respective companies’ websites. Emails requesting the CEO’s contact 
details were sent.  Three responders requested that I forward the PAIA request and they 
would ensure that the request was received by the CEO. One responder provided the CEO’s 
email address.  
3.9 The Promotion of Access to Information Act, (Act 2 of 2000) [PAIA] and using it 
The PAIA was used to formally request the information from the companies and the MCC. 
The Act itself was studied and analysed. The process involved in making PAIA requests was 
determined. ‘Form A’ stipulated by the Act had to be used for enquiries to public bodies; and 
‘Form C’ to be used to request information from the pharmaceutical companies. The reason 
for requesting the same information from the MCC as had been requested from the 
companies was to attempt to validate the responses of the pharmaceutical companies.  
3.9.1 PAIA fees 
The PAIA stipulates that both public and private bodies may charge a fee for the provision of 
information. The investigator requested for a waiver of the fees as the information requested 
was to be used strictly for academic purposes and the investigator was a full-time student 
with no income. 
3.9.2 Requests to pharmaceutical companies 
The letters to the individual companies were written and the completed Form C attached to 
the cover letter. The cover letter gave a brief introduction of the investigator and summarised 
the study and the request being made. Proof that the investigator was a student was attached in 
the form of a registration certificate from the University and a signed letter from the 
supervisor. The following insert summarises the request sent to each company. 
‘Could you please inform me what tests were done to show bioequivalence for 
registration of the attached list of generic (interchangeable multisource) medicines, 
manufactured and/or distributed by your company and please state whether a 
domestic or foreign reference product was used?’ 
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For the convenience of the CEO, a table was attached with columns to tick and to briefly state 
what tests were done. The requests were sent and the investigator waited for the responses. 
An example of the request to the companies is attached as Appendix 2. 
3.9.3 Request to the MCC 
The letter to the MCC was written and a completed Form A attached. As with the requests to 
pharmaceutical companies, proof of registration as a full time student and a copy of the 
supervisor’s letter were attached. In addition to the Registrar being asked for the registration 
details of the selected 20 products, she was also asked to comment on the answer to a written 
parliamentary question about the use of foreign reference products over a stated period of 
time. An excerpt from the request is given: 
‘... I am interested in the use of foreign reference products in the registration of generic 
medicines. I noted that the Minister of Health did not address this question when it was asked 
in parliament. (Question No 3021 - Internal Question Paper: 29 October 2010). The question 
was asked in relation to generic medicines registration ‘how many were used [registered] 
against foreign reference products as opposed to local innovator products?’  
‘The answer given was that the MCC does not use generic products for comparative purposes. 
It appears as if there may have been a misunderstanding of what a foreign reference product 
is, and I would like to ask this question again, as well as to ask whether a set of twenty 
specific products were or weren't registered using a foreign reference product...’ 
 
A table was included to make the requested information easier to provide, and this was also 
attached to the request. The request was sent and the investigator awaited a response. The 
request is shown in Appendix 3. The full parliamentary question referred to i.e. Question 
3021, is shown in Appendix 4.
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Chapter 4: Results 
 
4.0 Introduction 
This section presents the findings from the research. They are laid out in four parts. The first 
section shows the results from the enquiries made to the individual pharmaceutical 
companies. This is followed by a section outlining the ‘responsiveness’ scores (R-Scores), 
depicting the willingness of the pharmaceutical companies to disclose the requested 
information. The third section contains the responses received from the MCC and section 
four shows the results of the use of the Promotion of Access to Information Act (PAIA) in 
both private and public bodies. The enquiries made by the investigator are recorded in a 
smaller font and the responses received are presented in italics. 
4.1 Data from pharmaceutical companies. 
Of the requests that were sent to the nine companies, four companies provided the 
information. Two companies refused and three companies never replied.  
Table 4.1: Summary of nature of responses received 
Nature of response Number of companies 
Information provided  4  
Request refused  2  
No response  3  
 
Figure 4.1 represents the different responses. The number of companies and number of 
products are shown as x(y). 
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Figure 4.1: Nature of responses; number of companies; and products for each company  
 
4.2 Communication after initial request  
The interaction between the investigator and correspondents / CEOs from each company after 
the initial requests were made, and the first follow-up enquiries are outlined below. Section 
56(1) of the Act requires private bodies to respond within 30 days of receipt of the request. 
Sufficient time was therefore given before any follow up correspondence was sent to the 
companies. (Further communications are detailed in section 4.5). 
4.2.1 Company A 
No acknowledgement of receipt was received for the initial request of 1 June 2011, and a 
follow-up enquiry was made on the 22nd of July 2011: 
Dear Company A correspondent 
I would like to make an enquiry regarding the request for information using the Promotion of 
Access to Information Act that I made to you on the 1st of June 2011. I have to date not 
received an acknowledgment of receipt or a response. Kindly please advise. 
Regards 
9(20) 
Companies (products) 
No: 2(4) 
Yes: 
4(13) 
No responses: 3(3) 
Reasons 
stated: 1(3) 
Reasons not 
stated: 1(1) 
No 
hesitation: 
2(9) 
On provision of 
confidentiality 
agreement: 1(3) 
Partial 
information 
given: 1(1) 
Repeated Request 
No information provided: 
3(3) 
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On that same day, the correspondent responded as follows: 
‘Disclosures of this nature require overseas approval, which I am awaiting... 
although I do not think that this will be permitted. Please follow up in a week. 
Thanks’ 
4.2.2 Company B 
The initial enquiry was sent on 1 June, 2011. No acknowledgement of receipt was received 
by the investigator and the CEO was sent an enquiry regarding the request on the 22nd of July. 
No response was received. 
4.2.3 Company C 
An enquiry about the request was made on the 22nd of September, 2011 as the initial request 
had been set on the 28th of July. The regulatory pharmacist then responded, providing the 
requested information for all six products. Two products had been registered using DRPs and 
used only in vitro comparative dissolution studies. The remaining four products had been 
tested against FRPs, three using in vivo bioequivalence studies and one using in vitro 
comparative dissolution studies 
4.2.4 Company D 
Following the initial request of 5th of July 2011 and no acknowledgement of receipt having 
been received, a follow-up enquiry was made was made on the 19th of August. No response 
was received. 
4.2.5 Company E 
The initial request was sent on 20 June 2011 and a follow-up enquiry was made on the 22nd of 
July. 
On the 26th of July 2011, the following email was received from the correspondent: 
I have received your request and unfortunately our Company will not be able to assist you 
with the information you require. Your understanding is appreciated.  
Kind regards 
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4.2.6 Company F 
The initial request was sent on 1 June 2011. The regulatory pharmacist  suggested a telephone 
appointment to discuss the request. On the 27th of June the investigator called the regulatory 
pharmacist and after introductions and pleasantries, the regulatory pharmacist said: 
‘...The information you want will not be provided as it is part of the registration dossier that 
is submitted to the MCC...’ 
She further explained that the PAIA did not apply to such information. The investigator then 
asked for the presentation of this response formally in writing as per the written request she 
had received and this was agreed to. That same afternoon, a response was received. The 
regulatory pharmacist indicated that the product had been registered using a FRP. To indicate 
acknowledgement of receipt, the response was signed and sent back.  
4.2.7 Company G 
The initial request was sent on 1 June 2011. The CEO responded on the 28th of June and 
indicated that the information could not be disclosed based on Section 64 (1) subsection 2 of 
the PAIA:  
Mandatory protection of commercial information of third party 
 
64. (1) Subject to subsection (2), the head of a private body must refuse a request for access 
to a record of the body if the record contains— 
(a) trade secrets of a third party; 
(b) financial, commercial, scientific or technical information, other than trade secrets, of a 
third party, the disclosure of which would be likely to cause harm to the commercial or 
financial interests of that third party; or 
 
(c) information supplied in confidence by a third party, the disclosure of which could 
reasonably be expected— 
(i) to put that third party at a disadvantage in contractual or other negotiations; or 
(ii) to prejudice that third party in commercial competition. 
 
He further explained that since the information being requested was not made available to the 
general public, and constitutes trade secrets, disclosure could cause harm to the company and 
its license partners. In conclusion he did say that the decision could be reconsidered if the 
University guaranteed that the information would not be made public. (This response resulted 
in the development of a confidentiality undertaking which is discussed below.) 
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4.2.8 Company H 
The initial request was sent on 1 June 2011. No acknowledgement of receipt was received 
and a follow-up enquiry was sent on the 22nd of July. No response was received. 
4.2.9 Company I 
The initial request was sent on 1 June 2011. On 2 June an acknowledgement of receipt was 
received followed by a refusal of the request on the 10th of June:  
‘...After consideration of your letter, we regret to advise that we can unfortunately not 
provide you with the requested information based on section 64 and 65 of the Promotion of 
Access to Information Act 2 of 2000...’ 
Section 64 and 65 of the PAIA both deal with the protection of third parties. Section 64 is 
quoted above (4.2.7), and Section 65 is given below:   
65. The head of a private body must refuse a request for access to a record of the body if its 
disclosure would constitute an action for breach of a duty of confidence owed to a third party 
in terms of an agreement. 
 
4.3 Letter developed for unresponsive companies  
This letter was developed as a reaction to the lack of response of some of the companies (see 
Appendix 5). It did not change the content or nature of the initial request in any way. The 
letter was sent approximately 60 days after the initial request had been sent to companies A, 
B, D and H, explaining the companies’ legal obligation to respond to the PAIA request. 
According to Section 56 of the Act, a response to a request must be given within 30 days 
(unless a single extension of not more than another 30 days has been applied for in terms of 
Section 57):  
Decision on request and notice thereof 
56. (1) Subject to Chapter 5 of this Part, the head of the private body to whom the request is 
made must, as soon as reasonably possible, but in any event within 30 days, after the 
request has been received or after the particulars required in terms of section 
 
53(2) have been received— 
(a) decide in accordance with this Act whether to grant the request; and 
(b) notify the requester of the decision and, if the requester stated, as contemplated in section 
53(2)(e), that he or she wishes to be informed of the decision in any other manner, inform him 
or her in that manner if it is reasonably possible. (emphasis added) 
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4.4 Confidentiality undertaking 
Company G had indicated that their decision could be reconsidered if the University 
guaranteed the information would not be made public. As a result the investigator developed 
a confidentiality undertaking. (Appendix 6) This guaranteed that the identities of the 
companies and their products would not be disclosed and that pseudonyms would be used to 
refer to them in all publications. Pseudonyms in the form of ‘codes’ were then allocated to 
each company. The first nine letters of the alphabet were used (A-I). Each product was then 
designated a number after the letter for example company B had three products; B1, B2 and 
B3. The list of company pseudonyms, the respective product codes and pharmacological 
nature of the APIs are provided in Appendix 7. 
The confidentiality undertaking was co-signed by the supervisor of the project and the Dean 
of the Faculty of Pharmacy at Rhodes University. The confidentiality undertaking was sent to 
all the companies involved in the study on the 19th of August except company C to whom it 
was sent on the 22nd of September. For companies A, B, D and H, the confidentiality 
undertaking was sent along with the follow-up letter indicating that a response to a legitimate 
PAIA request is a legal obligation. 
4.5 Subsequent communication with pharmaceutical companies 
This section deals with the communications after the first follow-up enquiry was made. It will 
also cover the responses received after the companies had received the interventions in 4.3 
and 4.4 above.  
 
4.5.1 Company A 
As the correspondent had advised the investigator to follow-up the request after a week, a 
second enquiry was made on the 2nd of August.  
‘I would like to follow-up on my request for information according to PAIA dated 1 June 
2011. You advised me to do so after our communication on 22 July 2011. Please advise.’ 
No response was received. The confidentiality undertaking and a letter highlighting Section 
56 of the PAIA were sent on 19 August 2011, and still no response was received. A final 
enquiry was sent on the 5th of October no response has been forthcoming. 
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4.5.2 Company B 
The CEO responded on the 22 August 2011, providing the requested information (after the 
confidentiality undertaking had been sent on 19 August). All three products had been 
registered using FRPs and both comparative dissolution and in vivo bioequivalence studies 
were used to prove equivalence for purposes of registration. 
4.5.3 Company C 
See above. (The initial follow-up enquiry was sent with the confidentiality undertaking 
attached and the regulatory pharmacist sent the requested information immediately.)  
4.5.4 Company D 
No response was received to the follow up documents. As a final follow-up, an enquiry was 
made on the 5th of October. No response has been received. 
4.5.5 Company E 
On the 11th of August 2011 a query was sent to Company E requesting reasons for not 
acceding to the initial request. No response was received. The confidentiality undertaking 
was subsequently sent on 19 August. A final enquiry was made on the 14th of October 2011. 
No response was received. 
4.5.6 Company F 
On the 12th of July 2011, the regulatory pharmacist was asked about the second part of the 
request i.e. tests done to prove equivalence. An excerpt from the letter is given below: 
‘...I would like to acknowledge receipt of your response dated 27 June 2011. Thank you very 
much for the information that you have provided. Lastly, I would like to ask about the second 
part of my request; The test(s) done to prove equivalence. Was it dissolution testing and/or 
bioequivalence studies? I would be very grateful if you could furnish me with that last bit of 
information. If not, please may you in writing please give reasons as to why the information 
may not be disclosed...’ 
On the 13th of July, a response (Appendix 8) was received, in which it is implied that both 
bioequivalence studies and dissolution testing had ‘been conducted’. The regulatory 
pharmacist explained the requirements according to the MCC for use of a FRP in the 
registration of a generic medicine. The pharmacist suggested that the investigator familiarise 
herself with the MCC guidelines.  
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This response was signed in acknowledgment and returned as per request. As there had been 
no unequivocal confirmation of the tests done to prove equivalence, a follow up email was 
sent to the regulatory pharmacy on the 19th of August to confirm that both bioequivalence and 
dissolution studies had been done to prove equivalence. The confidentiality undertaking was 
included with this. No response was received. 
4.5.7 Company G 
On receipt of the confidentiality undertaking, the CEO immediately responded referring the 
investigator to the Head of pharmaceutical development, who provided all the information 
requested on the 15th of September. Of the three products in question, two were registered 
using FRPs. Testing for both these products had involved bioequivalence studies and one had 
had additional comparative dissolution studies. The third product was registered using a non-
FRP and comparative dissolution studies were carried out to prove equivalence. 
4.5.8 Company H 
As no response was received after having sent the confidentiality undertaking and the letter 
highlighting Section 56 of the PAIA, a final enquiry was made on the 5th of October. The 
CEO has not responded. 
4.5.9 Company I 
On the 19th of August the request was sent again along with the confidentiality undertaking in 
the hope that the CEO would reconsider his decision to refuse the request. On the 23rd of 
September the CEO replied, refusing the request a second time, (see Appendix 9). The CEO 
indicated that he was of the view that the PAIA request was not consistent with the intention 
of the Act neither did it conform to the Act as they did not consider the right to academic and 
scholarly endeavour ‘a recognised right in terms of the Constitution’.  
Table 4.2 shows the dates when the initial requests were sent, when key responses and the 
final responses were received and when the confidentiality agreement (CU) was sent. 
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Table 4.2: Dates of communication with companies 
Pseudonym Products Date 1st request 
was sent 
Date CU was sent Date of final response 
A A1 01/06/2011 19/08/2011 X 
B B1-B2 01/06/2011 19/08/2011 22/08/2011 
C C1-C6 28/07/2011 22/08/2011 22/08/2011 
D D1 05/07/2011 19/08/2011 X 
E E1 20/06/2011 19/08/2011 X 
F F1 01/06/2011 19/08/2011 13/07/2011 
G G1-G3 01/06/2011 19/08/2011 28/09/2011 
H H1 01/06/2011 19/08/2011 X 
I I1-I3 01/06/2011 19/08/2011 23/09/2011 
CU = Confidentiality Undertaking; X = No final response provided 
Table 4.3 summarises and shows the responses from each company regarding each product. 
Responses were received for 13 of the 20 products in question. Ten of the 13 products were 
registered using FRPs. 
Table 4.3: Results from responsive companies 
Company  Product  Nature of 
product 
FRP 
Used?  
Tests done  Higher dose 
Registered? 
B  B1  Anti-cholesterol Yes  Bioequivalence and 
comparative dissolution 
No 
 B2  Vasodilator Yes  Bioequivalence and 
comparative dissolution 
No 
 B3  Anti-depressant Yes  Bioequivalence and 
comparative dissolution 
No 
C  C1  Anti-epileptic No  Comparative dissolution Yes 
 C2  Anti-
hypertensive 
No  Comparative dissolution No 
 C3  Anti-
hypertensive 
Yes  Bioequivalence No 
 C4  Mineral 
supplement 
Yes  Comparative dissolution No 
 C5  Analgesic Yes  Bioequivalence No 
 C6  Anti-arrhythmic Yes  Bioequivalence No 
F  F1  Anti-
inflammatory 
Yes  Bioequivalence and 
comparative dissolution 
No 
G  G1  Anti-arrhythmic Yes  Bioequivalence and 
comparative dissolution 
No 
 G2  Anti-
inflammatory 
No  Comparative Dissolution Yes 
 G3  Anti-epileptic Yes  Bioequivalence No 
  
 55 
4.6 The ‘level of responsiveness’ of the pharmaceutical companies 
This is depicted as an ‘R-Score’. It is based on the information that was provided by the 
companies. The score represents the willingness of the companies to voluntarily19 provide the 
requested information.  The highest possible score was achieved when the company provided 
all the requested information and the lowest score was received when the company failed to 
respond to the request at all. Tables 4.4 and 4.4A below show the R-score and interpretations 
for the nine companies involved in the study.  
Table 4.4: R-Score for pharmaceutical companies 
RRRR 
Information provided 
with no hesitation 
RRR 
Information provided after 
confidentiality undertaking 
RR 
Some of the requested 
information provided 
B G F 
C   
R 
Requested declined, 
reasons given 
RX 
Request declined, reasons 
not given 
X 
Request ignored 
I E A 
  D 
  H 
 
Table 4.4A: R-Score for pharmaceutical companies A - I 
Company R Score 
A X 
B RRRR 
C RRRR 
D X 
E RX 
F RR 
G RRR 
H X 
I R 
 
                                                             
19 As there were errors in the wording of the PAIA requests, the responses received can be considered voluntary 
disclosures.  
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4.7 Request to the MCC for information 
The PAIA request was dated 24 May 2011. The Registrar of Medicines replied and referred 
the investigator to a Mr GJ Wissing, the Deputy Information Officer (DIO) of Legal Services 
of the Department of Health. The request was immediately forwarded to him. A follow-up 
enquiry was made on the 20th of June as no acknowledgement of receipt had been received 
from him. A response was received on the 20th of July when the request was refused in terms 
of Section 45 (b) of the PAIA (Appendix 10).  
 
(b) the work involved in processing the request would substantially and unreasonably divert 
the resources of the public body. 
 
The DIO also cited Section 36 of the PAIA: Mandatory protection of commercial information 
of third party and recommended that the information be obtained directly from the 
pharmaceutical companies. 
 
4.7.1 Evaluation of the Initial response 
 
The MCC refusal was analysed and the investigator decided to lodge an internal appeal.  
 
4.8 Internal appeal 
 
The Internal appeal was lodged in terms of Section 74 of the PAIA. It consisted of a cover 
letter, a completed compulsory Form B, and a document titled ‘the grounds of appeal’. The 
grounds of appeal are a justification as to why the information should be disclosed to the 
investigator (see Appendix 11). An excerpt from the grounds of appeal is given: 
 
1. ‘...It is not unreasonable to anticipate that the Regulatory Authority should be able to 
access the product files of any product at any given time. 
2. Section 15(7) of the Medicines and Related Substances Act (Act 101 of 1965) states 
that:  
Any registration under this section, including the registration of medicines 
already registered . . . may be made subject to such conditions as may with 
regard to the succeeding provisions of this section be determined by the council. 
As every medicine is registered with ‘conditions of registration’ it must mean that should any 
query about the basis for a particular condition of registration be raised, the MCC can at any 
time access the product files (dossier) of a medicine’s application. Accessing the product files 
would therefore surely be a normal part of the regulatory authority's everyday activities and 
Section 45(b) of the PAIA (Act 2 of 2000) would not apply...’ 
The appeal was sent to the Registrar and the investigator was referred again to the DIO. A 
response was awaited. On the 11th of October a follow-up enquiry was sent to the DIO.  
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4.9 Final MCC response 
A second refusal of the request was received from the DIO on the 21st of October. (Appendix 
12). The decision to dismiss the appeal was stated to have been made by the relevant 
authority (the Minister of Health), and Sections 36 and 45 of the PAIA were given as grounds 
for the MCC’s refusal. These are: 
 
Mandatory protection of commercial information of third party 
 
36. (1) Subject to subsection (2), the information officer of a public body must refuse a 
request for access to a record of the body if the record contains— 
(a) trade secrets of a third party; 
(b) financial, commercial, scientific or technical information, other than trade secrets, of a 
third party, the disclosure of which would be likely to cause harm to the commercial or 
financial interests of that third party; or 
(c) information supplied in confidence by a third party the disclosure of which could 
reasonably be expected— 
(i) to put that third party at a disadvantage in contractual or other negotiations; or 
(ii) to prejudice that third party in commercial competition. 
(2) A record may not be refused in terms of subsection (1) insofar as it consists of 
information— 
(a) already publicly available; 
(b) about a third party who has consented in terms of section 48 or otherwise in writing to its 
disclosure to the requester concerned; or 
(c) about the results of any product or environmental testing or other investigation supplied 
by, carried out by or on behalf of a third party and its disclosure would reveal a serious 
public safety or environmental risk. 
(3) For the purposes of subsection (2)(c), the results of any product or environmental testing 
or other investigation do not include the results of preliminary testing or other investigation 
conducted for the purpose of developing methods of testing or other investigation. 
 
Manifestly frivolous or vexatious requests, or substantial and unreasonable 
diversion of resources 
 
45. The information officer of a public body may refuse a request for access to a record of the 
body if— 
(a) the request is manifestly frivolous or vexatious; or 
(b) the work involved in processing the request would substantially and unreasonably divert 
the resources of the public body. 
 
The DIO further stated that the motivation for the appeal had failed to indicate how the 
disclosure of these records would give evidence of contravention of a law and/or a serious 
public risk.  
 
The DIO did not however respond to that part of the request regarding the MCC PAIA 
manual. On the 26th of October 2011, the DIO was sent another letter, acknowledging receipt 
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of the reply and again requesting a copy of the MCC’s PAIA manual (Appendix 13). As a 
final follow up, an enquiry was made on the 15th of November. No response was received and 
it was concluded that the MCC does in fact not have a PAIA manual. 
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Chapter 5: Discussion 
 
5.0 Introduction 
This chapter analyses and discusses the results from chapter four and the objectives set for 
the research (page 4).  
The use of an action research methodology within a case study framework proved to be a 
most appropriate approach to conducting this study. The information obtained from the 
pharmaceutical companies, followed by the R-Score20 analysis, the results from the 
Medicines Control Council (MCC), issues related to the MCC guidelines, the MCC’s 
regulatory role, the interchangeability of medicines, the tender system, concerns about 
foreign reference products (FRPs) and dissolution testing, intellectual property rights, legal 
liability and finally the application of the Promotion of Access to Information Act, Act 2 of 
2000 (PAIA) in the context of this study are all discussed. This includes the use of the PAIA 
from a ‘layperson’s’ perspective and some of the errors made.  
The data from chapter four, and the literature from chapter two are included. Unless 
otherwise stated the MCC guidelines referred to in this chapter are the June 2011 
Pharmaceutical and Analytical (P&A) and Biostudies guidelines; and the March 2011 
Dissolution guideline. 
The case study framework with a deliberately small sample size means that the results cannot 
in any way be generalised. No definitive conclusions about the use in South Africa of foreign 
reference products or the tests used to demonstrate therapeutic equivalence in the registration 
of generic medicines, can be made. However, it may provide some background information 
for further research. 
5.1 Responses from pharmaceutical companies 
The decision to inquire about modified release and BCS IV preparations was a deliberate one 
in that the MCC guidelines do not recommend dissolution tests ‘on their own’ for registration 
of these products. As all modified release products have to show evidence of the mechanism 
of modified release of the reference product, this information was not requested in this study.  
                                                             
20  R-Score: A ‘responsiveness score’ developed to depict the willingness of the pharmaceutical 
companies to voluntarily respond to PAIA questions. 
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According to the MCC’s Pharmaceutical and Analytical guideline, modified release dosage 
forms include ‘delayed-release dosage forms’, and ‘extended-release dosage forms’. It is 
noted in the guideline that the terms ‘controlled release’, ‘prolonged action’ and ‘sustained 
release’ are used synonymously with ‘extended release’.[9] 
For five of the thirteen products about which information was provided, both in vivo and in 
vitro methods were used. As is the norm and part of the rationale for the very existence of 
generic medicines, none of the products had undergone clinical trials. Of the thirteen 
products, ten used a FRP as a comparator for registration. The sources (origins) of the 
different FRPs used as comparators for those products were not requested or identified. If 
none of the seven products for which no information was made available were registered 
using a FRP, this would mean that 50% of the small sample chosen were registered against a 
FRP. This seems at face value to be significant (in the sense of important rather than 
statistically significant).  
In vitro comparative dissolution studies were used as a standalone means of approval for four 
of the thirteen products, (three with DRPs and one with a FRP as comparator). It is possible 
that the one product registered using a FRP as comparator and only in vitro dissolution 
studies could have been given a biowaiver upon motivation by the applicant, but no evidence 
of this is available. In future research it would be worth asking whether or not a waiver had 
been granted if comparative dissolution studies have been used as a standalone means of 
approval. The use of FRPs for purposes of registering generic medicines seems to be a reality 
in the pharmaceutical industry in South Africa. It would be interesting if further research 
could be done to determine the percentage of generic medicines that have been registered 
using FRPs as comparators. It would also be useful to determine the attitudes of prescribers 
and dispensers towards the use of FRPs for registration purposes and whether or not they 
believe this is information that should be made available to them and why. 
5.1.2 Modified release products – biowaivers  
Biowaivers for in vivo equivalence studies may be granted when a higher dose of the same 
product has already been registered. Dissolution testing and comparison of dissolution 
profiles may in certain instances then be used alone for lower doses.[65]  
For the three products where the DRP was used i.e. products C1, C2 and G2, only 
comparative dissolution studies were used for registration. Biowaivers may be granted for 
modified release preparations when the proposed product is proportionally similar to a 
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product that has already been approved and is on the market. Conditions come with this 
exemption. These conditions include that the lower strengths of the product are in the same 
dosage form as the higher strength, that they exhibit the same release properties and are 
proportionally similar in their active and inactive ingredients. The products must also be 
manufactured by the same manufacturer and at the same site as the registered generic.[65,67] 
Higher strengths of the medicines are available for C1 and for G2. It is therefore reasonable 
to assume that these higher strengths were appropriately tested before approval and C1 and 
G2 were eligible for bio-waivers and comparative dissolution testing was sufficient for 
registration. The manufacturers were however not specifically asked about the testing of the 
higher strengths and this is a limitation of this study. C2 however does not have a higher 
strength and would seemingly not have qualified for a bio-waiver.  
Products C1-C6 and G3 all had only one of the required tests done. The four products from 
Company C that were registered using only in vivo bioequivalence studies were all registered 
against FRPs. It should be a concern that dissolution tests were not carried out as well. As G3 
is an anti-epileptic drug registered against a FRP and no higher strength is available, it is of 
possible greater concern given the serious nature of epilepsy and the possibilities of break-
through seizures with a modified release product occurring. 
5.1.3 Product C4 
Product C4 is of particular interest. It was the only product registered against a FRP where 
only comparative dissolution testing and no bioequivalence studies were done. C4 does not 
qualify for a bio-waiver as it is made in a single strength only. No enquiry was made to the 
company as to why bioequivalence studies were not done on this product. It seems unlikely 
that the members of the relevant committee of the MCC would have overlooked this, but it is 
possible that the pharmaceutical industry itself does not always adhere to the regulatory 
authority’s guidelines, and the product ‘slipped through the cracks’. However C4 is a mineral 
supplement. In general mineral supplements are not required to undergo bio-availability 
studies. Whether mineral supplements with modified release properties are required to 
undergo bio-equivalence studies for purposes of registration is not clear and the MCC 
guidelines do not make specifications for modified release mineral supplements. It could be 
argued that a bioequivalence study was not necessary. On the other hand an overdose of this 
particular mineral supplement could have life threatening consequences, so perhaps a blanket 
approach to modified release mineral supplements being registered based on comparative 
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dissolution testing alone is not appropriate.  No enquires were made to the MCC and 
manufacturer of C4 to explain why it was seemingly exempted from bioequivalence studies 
5.1.4 BCS Class IV product 
As the company to which the request for information regarding the BCS class IV product was 
sent did not respond, it is not known whether or not it was registered against a FRP or what 
tests were used. It may have been a better decision for this study to use both BCS class IV 
generic medicines listed in the Generics Dictionary rather than just one of them. BCS class 
IV products, which are problematic in terms of permeability and solubility, require in-vivo 
bioequivalence studies.  
5.2 The confidentiality undertaking 
The confidentiality undertaking became a loop in the action research process. The wording of 
the initial request was not changed, however anonymity was introduced into the research as a 
result of one of the companies stating that they would provide information on condition that a 
confidentiality agreement was incorporated. Action research techniques allow one to evaluate 
and introduce additional aspects into the study, modify it where necessary and continue. This 
proved to be an advantage of using this methodology for this study.[114] 
5.2.1 Responsiveness of the pharmaceutical companies 
 
The ‘R-Score’ was initially conceptualised based on the Australian Prescriber Journal’s 
transparency score (T-score). [110,111] As the PAIA requests made to the companies 
erroneously asked for specific information within records instead of specifying the records 
which the researcher wished to access, the companies were under no obligation to provide the 
information in terms of the PAIA. That they did so voluntarily may indicate that they too did 
not fully comprehend the parameters and requirements of the PAIA. 
The ‘R-Score’ therefore simply represents the responses received voluntarily from the 
pharmaceutical companies. Differences within categories were catered for. For example, 
though companies B, C, F and G all provided information, it was under different 
circumstances and the nature of the information was different. This led to companies being 
assigned different ‘R-Scores’. Companies B and C received the highest score of ‘RRRR’ and 
can be stated to have been the most responsive of the nine companies as the full information 
was provided and no hesitation or reservations were shown. The time taken to furnish 
responses to the requests was not incorporated into the scores as it was acknowledged that 
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CEOs have very busy schedules (and the PAIA makes it the CEO’s responsibility to respond, 
although it does stipulate a time line of 30 days with the option of a request for a single 
extension of another 30 days). Company G agreed to provide the information only on 
condition of guaranteed anonymity and hence received the second highest score of ‘RRR’.  
The ‘RR’ score indicated that company F had provided the information but hesitation was 
clear, and there was some vagueness in the response. Not surprisingly the regulatory 
pharmacist for company F demonstrated an awareness and knowledge of the MCC 
requirements for registration. After stating these, she wrote: 
‘As such, if a foreign reference product was used in the registration of a generic medicine, it 
follows that both a bioequivalence and dissolution study has been conducted.’ (emphasis 
added) 
It would seem the intention was that the researcher should assume that it was obvious that the 
appropriate studies had been done for the product in question, F1. (Appendix 8) The 
regulatory pharmacist’s response could be perceived as not wanting to be specific and make a 
definitive statement – for whatever reason. Efforts to clarify and verify the information 
received no response.  
In the cases where the companies refused the requests outright, the only differentiation made 
to the ‘R-score’ was whether or not a reason was given for the refusal. In terms of the PAIA, 
a reason had to be provided as to why the request was denied. Companies I and G were 
clearly aware of this and quoted Sections 64 and 65 of the PAIA as reasons for refusal. 
Company E however failed to give any reasons. 
The allocation of an ‘R-score’ of ‘X’ was for companies who did not provide the requested 
information had no divisions as all companies were unresponsive. Although company A 
acknowledged receipt of the request as compared to companies D and H, no information was 
actually then provided. It is a possibility that the requests for information were not taken as 
seriously because a student was making them. It is also possible that these three companies 
identified that the PAIA had been used incorrectly, and that they had no legal obligation to 
respond. For companies D and H, it could be argued that the email addresses used were not 
viable or were wrong, however this is unlikely. The email address for the CEO of company D 
was provided by the correspondent from the company and no notification of ‘failure of 
delivery’ or ‘out of office’ was received for either company.  
Companies G and I indicated in their refusals that they were protecting unnamed third parties. 
This response is specified in the PAIA itself. The companies may have felt that this particular 
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information, if it became public knowledge might reduce sales or harm the company image. 
Prescribers and/or dispensers of their medicines might become suspicious of products 
evaluated against foreign comparators. This could in turn have adverse consequences for the 
companies. The irony is that FRPs may well be quite acceptable in terms of quality, safety 
and efficacy – but in South Africa this is largely unknown and further research should be 
done to verify this. 
5.2.2 Intellectual property  
Protection of intellectual property rights (IPR) could be one of the reasons why companies 
would not wish to disclose information. However, no specific details about the names and 
sources of reference products were requested. The request also did not enquire about 
manufacturing processes or formulations which can be said to be ‘owned’ by the companies. 
These are the kinds of details that would generally be viewed as sensitive and considered as 
intellectual property.[116] Furthermore bioequivalence and dissolution tests are not novel 
tests that can be said to ‘belong’ to a company. They are used across the world in the 
pharmaceutical industry and the MCC guidelines describe how these tests are to be 
performed for the registration of medicines in South Africa. Which tests were done in 
registering a product would not be considered intellectual property since the tests required to 
prove equivalence are public information.[65,67] It is possible that the companies were 
importing their products and this was what was meant by the ‘third parties’. Some of the 
companies have ‘parent companies’ overseas, which is implied in Company A’s response. It 
is possible that the ‘third parties’ referred to are these parent companies. 
5.3 Response from the MCC 
The first thing to be noted from the MCC’s response to the initial request was that the MCC 
has no up to date electronic database containing the information about all registered 
medicines. Dossiers are very large collections of documents and creating the electronic 
storage of all the details in them would be a gargantuan task for all the registered products 
already on the South African market. That being said, the fact that the MCC is unable to 
easily and rapidly access details regarding medicines that have been registered is cause for 
concern. Their failure to provide the mandatory PAIA manual is also cause for concern. As 
much as this is so, it is acknowledged that the request made to the MCC was inappropriately 
phrased. The request (Annexure 3) was for the ‘contents of records’ and not ‘specified 
records’ as required by the PAIA. The MCC therefore was not obliged to provide the 
information to the investigator and correctly refused to do so. 
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5.3.1 The response to the parliamentary question 
A component of the request to the MCC was the inclusion of the Minister of Health’s 
response to a written parliamentary question. Responses to parliamentary questions can be 
particularly useful as they are required to be truthful, although there are anecdotes about how 
certain questions are avoided or minimised. Answers to parliamentary questions are also in 
the public domain. Parliamentary questions can be used to obtain information, or at times 
may have a more devious objective such as embarrassing government. As the parliamentary 
question had been put to the Minister of Health by a member of the opposition party, one can 
assume that it was treated with caution by government. The response given was in this 
researcher’s view inadequate. The intention of the question (as understood by the researcher) 
was that it would give details of the extent (perhaps as a percentage) of the use of foreign 
reference products in the registration of generic medicines. The Minister’s response which 
was that the MCC does not use generic medicines as comparators indicates a possible 
deliberate avoidance of directly providing the information requested. The Registrar however 
was of the view that the question, as asked, had been answered appropriately and stated that 
the question had not asked about the extent to which FRPs are used as comparators in 
registering generic medicines. Technically the Registrar’s view is incorrect because if no 
innovator product is on the market a ‘generic’ may well be used as a comparator for 
registration of another generic medicine. The response could be interpreted as being an 
indication that the answer is unknown. However a rough estimate in words could well have 
been provided such as ‘most’ or ‘minimal’ generics are registered using FRPs as 
comparators. 
The use of FRPs as comparators appears to be widespread however, and their use in the small 
sample in this study seems to bear this out.  
5.3.2 The internal appeal and second refusal 
On refusal of a PAIA request from a public body, an internal appeal can be made in terms of 
Section 74(1) of the Act. An internal appeal is submitted by the requester calling for the 
decision regarding the request to be reconsidered. The appeal is accompanied by the grounds 
of the appeal to justify why the information is to be furnished. In their response to the appeal, 
the letter signed by the DIO of the Department of Health again made reference to both 
Sections 36 and 45 as in the initial refusal. Particular emphasis was placed on Section 45(b) 
and it was stated that the Minister of Health, as the higher authority to whom the internal 
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appeal had been referred was ‘of the opinion that it would be completely unreasonable for the 
MCC to have to go through each and every dossier to answer (1) in your original request.’ 
In the PAIA CSN shadow report a lack of resources is noted as a reason why the 
implementation of PAIA is a challenge. Poor records management is also stated as a factor 
affecting implementation.[100] The response to the internal appeal quoting Section 45(b)21 is 
of a similar nature to the findings in the shadow report. 
5.4 Changes in the MCC guidelines.  
In considering the MCC’s regulatory role, guidelines are not considered to be strict rules or 
the law. They are seen as a guide to show how things ought to be done. The guidelines begin 
with a statement that they are ‘recommendations’ for completing applications for registration 
of medicines. The guidelines make it clear that they are not to be considered an exclusive 
approach and that additional information may be required. Alternative approaches may 
furthermore be suggested with sufficient justification. Guidelines for industry are also 
provided by the WHO, and in other countries e.g. USA and Europe.[120-122]  
The MCC guidelines have changed over the years, including those applying to the use of 
FRPs and the tests required for the proof of equivalence. The guidelines seem to reflect an 
increasing flexibility on the part of the regulatory authority since the initial introduction of 
generic medicines. From an initially fairly rigid process where the only recognised reference 
product was the innovator product, there are now four options for choice of a reference 
product in the most recent Pharmaceutical and Analytical guideline. With dissolution testing 
being accepted as a means of proving equivalence for certain predefined products, a cheaper 
and faster means was provided to the industry. Furthermore, the use of dissolution studies has 
become widespread and is used even in cases where it may not be the most appropriate test. 
Circular 14/89 of 1989 only gives indications of when dissolution studies may be used. They 
do not specify instances in which they are not appropriate. For example, dissolution testing 
would presumably be entirely inappropriate for topical medicines. 
It is not clear to what extent dissolution studies are being used on their own for the 
registration of generic modified release preparations – despite the fact that the guidelines 
state that in vivo bioequivalence studies must be carried out for these products’ registrations. 
It is argued that it would be unreasonable to require every generic medicine to undergo full 
clinical trials. This would be time consuming, expensive and unethical.[58] However not 
                                                             
21  ‘the work involved in processing the request would substantially and unreasonably divert the resources 
of the public body’ 
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performing the clinical trials must not result in any compromise of quality, safety and 
efficacy of the medicines. Requirements for both in vitro dissolution studies and in vivo 
bioequivalence studies must be clearly stated without any ambiguity or room for 
misinterpretation. The NAPM22 itself has stated: 
‘Generic medicines are subject to the same scrutiny by regulatory authorities as products of 
original research. Stringent requirements of South Africa’s Medicines Control Council ensure 
that the quality and efficacy of generic medicines mirror that of the original product...’.[45] 
(emphases added) 
The MCC’s June 2007 Pharmaceutical and Analytical guideline made the following 
cautionary statement: 
‘A product that has been approved based on comparison with a non-domestic reference may 
or may not be interchangeable with currently marketed domestic products.’[77] 
The June 2011 Pharmaceutical and Analytical guideline does not contain the same warning. It 
is fair to assume that in placing this caution in the 2007 guideline the regulatory authority is 
aware that interchangeability between products registered using FRPs and the DRP may not 
be ideal or is even potentially problematic. This statement is in line with what Kanfer states: 
‘In the absence of specific confirmatory data i.e. comparative bioavailability data, a non-
domestic [foreign] comparator product used as a the reference product in a bioequivalence 
study involving a generic product intended for a particular domestic market cannot be 
assumed [or considered] to be bioequivalent to the domestic innovator product.’[22] 
Perhaps prescribers, dispensers and possibly even patients should be aware of medicines 
where no comparative bioavailability data have been submitted by the applicant or evaluated 
by the MCC, so that an informed decision can be made about generic substitution by these 
stakeholders. This is particularly relevant in the South African context where dispensers of 
medicines are required by law to substitute generic products unless the prescriber has 
prohibited it or the patient refuses it. 
The prescribers, dispensers and patients would usually have no interest in checking industry 
guidelines to obtain information even though they are publicly available on the MCC’s 
website. They are most likely unaware of the guidelines and no information is provided to 
these stakeholders about the use of FRPs or the tests used in registering products. The system 
is thus geared towards ‘blind trust’ in the regulatory authority.  
Consideration should be given to amending the Regulations to the Medicines Act to include 
providing prescribers and dispensers with the origin of the comparator reference product and 
                                                             
22  NAPM: National Association of Pharmaceutical Companies.  
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the tests used to prove equivalence. This could possibly be included in the medicines’ 
package inserts. Similar information in simplified yet accurate language could be included in 
the mandatory patient information leaflets if deemed desirable23. Consideration would have 
to be given as to whether or not such information would also need to be included on the 
labels and outer packaging of the products. The WHO encourages regulatory authorities to 
communicate with their clients regularly, acknowledging the right of citizens to receive 
accurate and appropriate information from the authority, and especially about medicines 
marketed in their country.[1] 
The question as to why the cautionary note was excluded from the updated version of the 
Pharmaceutical and Analytical guideline must be asked. Was it a result of pharmaceutical 
industry pressure on the secretariat of the MCC? Was it pointed out to the Council members 
of the MCC that it had been removed when they approved the new guideline? Does the MCC 
now believe that products approved based on comparison with a non-domestic reference are 
‘always’ interchangeable with currently marketed domestic products? 
5.5 The Role of the MCC 
The MCC has the statutory responsibility to ensure that all available medicines have satisfied 
the requirements for quality, safety and efficacy.[61,62] While this study may suggest over-
flexibility in generic medicines’ registration, Tobin concludes that the MCC ‘over-regulates’ 
the pharmaceutical industry in its pharmaceutical policies.[123] Her study compared the 
MCC’s requirements with the requirements and guidelines of the USA and EU medicines 
regulatory authorities.24  
Tobin’s conclusions were that the MCC seemed to take a more academic approach when it 
comes to medicines registration, while the industry took a more practical (pragmatic) stance. 
Some of the ‘additional’ requirements of the MCC (compared to the overseas authorities) 
were viewed to be unnecessary, not adding extra value to the product and often impractical 
by the industries.[123] As a regulatory authority, the MCC is required to exercise its authority 
in terms of the legislation (and the parliamentary mandate) for the protection of the people of 
South Africa. The MCC can even be commended for taking a more rigorous stance as it 
seems to highlight a more patient-focused, rather than industry-focused approach with 
regards to medicines’ registration. (It would seem however that the increasing flexibility that 
                                                             
23  Issues of adherence (compliance) would need to be carefully considered amongst others. 
24  The Food and Drugs Administration (FDA) and European Medicines Agency (EMA) respectively 
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has been developing over the years may be shifting more towards an industry-friendly 
approach.) It should be noted that the MCC relies heavily on academics to work in its 
committees and as members of the Council itself. The FDA and EMA rely more heavily on 
full time employees. The latest amendment of the Medicines Act (Act 72 of 2008) which has 
been assented to by the President but not yet promulgated25, will abolish the MCC and 
replace it with a structure closer to that of the FDA.  
The 2011 High Court case concerning the MCC’s resolution that dextropropoxyphene (DPP) 
be withdrawn was won by the MCC against Adcock Ingram. This is an indicator of the vital 
role that the MCC plays in the protection of the people of South Africa, and that in some 
areas the MCC is fulfilling its mandate.[124,125] 
5.6 Interchangeability 
Another potential problem area needing to be addressed is that of the meaning of 
interchangeability. It is defined in the Medicines Act (Section 1) as follows: 
'interchangeable multi-source medicine' means medicines that contain the same active 
substances which are identical in strength or concentration, dosage form and route of 
administration and meet the same or comparable standards, which comply with the 
requirements for therapeutic equivalence as prescribed 
The prescribed requirements for therapeutic equivalence are defined in Regulation 2 of the 
Regulations to the Medicines Act as follows:  
A medicine is considered therapeutically equivalent to another medicine if both medicines- 
 
(a) are pharmaceutically equivalent, i.e., contain the same amount of  active 
substances in the same dosage form, meet the same or comparable standards 
and are intended to be administered by the same route; and 
(b) after administration in the same molar dose, their effects with respect to both 
efficacy and safety are essentially the same. 
 
Therapeutic equivalence is determined from comparative bioavailability, pharmacodynamic, 
clinical or in vitro studies which meet the requirements and accepted criteria for 
bioequivalence as determined by the Council.  
 
The Regulations to the Act define bioequivalence as follows: 
 
                                                             
25 In March 2012 this version of the Medicines Act was returned to parliament as the ‘Medicines and Related 
Substances Amendment Bill 2012’. 
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‘bioequivalence’ means the absence of a significant difference in the bioavailability between 
two pharmaceutically equivalent products under similar conditions in an appropriately 
designed study’ 
 
Bioavailability is not defined in the Act or Regulations but in the MCC’s ‘Biostudies 
Guideline’ Version 5, June 2011 it is defined as:  
‘Bioavailability refers to the rate and extent to which the API, or its active moiety, is absorbed 
from a pharmaceutical product and becomes available at the site of action. It may be useful to 
distinguish between the ‘absolute bioavailability’ of a given dosage form as compared with 
that (100 %) following intravenous administration (e.g. oral solution vs. intravenous), and the 
‘relative bioavailability’ as compared with another form administered by the same or another 
non-intravenous route (e.g. tablets vs. oral solution).’ 
 
These three definitions are shown in Table 5.1 
Table 5.1 The elements of the definitions for generic medicines 
Interchangeable multi-
source medicine (generic 
medicine) 
Therapeutic equivalence Bioequivalence 
 Pharmaceutically equivalent Pharmaceutically equivalent 
same active substances  Same amount active substances [Same amount active substances; 
same dosage form; same route of 
administration; same or 
comparable standards] 
Identical in strength 
(concentration) 
Identical dosage form Same dosage form 
Identical route of 
administration 
Same route of administration 
Meet same or comparable 
standards 
Same or comparable standards 
Prescribed requirements for 
therapeutic equivalence 
  
 After administration in the same 
molar dose, their effects with 
respect to both efficacy and 
safety are essentially the same. 
[After administration in the same 
molar dose, their effects with 
respect to both efficacy and safety 
are essentially the same.] 
 Determined from comparative 
bioavailability, 
pharmacodynamic, clinical or in 
vitro studies which meet the 
requirements and accepted 
criteria for bioequivalence 
[Determined from comparative 
bioavailability, pharmacodynamic, 
clinical or in vitro studies which 
meet the requirements and 
accepted criteria for 
bioequivalence] 
  No significant difference in 
bioavailability under similar 
conditions in appropriately 
designed study. 
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Put simply, a generic medicine must be i) therapeutically equivalent, ii) pharmaceutically 
equivalent and iii) bioequivalent.  
The question must be asked whether or not dissolution testing and bioequivalence studies can 
be relied on to show that ‘after administration in the same molar dose, their effects with 
respect to both efficacy and safety are essentially the same’. It could be argued that efficacy 
and safety could in fact only be shown with clinical studies. 
5.6.1 The Tender System in South Africa 
The purpose of the tender system is to allow government, which supplies medicines at no 
charge to the majority of the population, to attempt to do so in a more cost effective manner. 
According to the National Drug Policy of SA (1996), the use of generic medicines shall be 
prioritised; this is mandated in the MARS26, Section 22F to reduce the cost of medicines. 
Contracts for tenders may range from six months to one year or more. This means that 
patients who depend on the public sector for their medicines may not receive medicines that 
look the same every month, even if they contain the same concentrations of the active 
ingredients. This lack of consistency particularly affects patients on chronic medicines. If a 
supplier defaults (or is unable to fully supply medicines for the duration of the tender) and 
replacements are obtained from another manufacturer, it means the patients will be receiving 
a different generic product. It is possible that this generic product was registered against a 
FRP and has not been proven bioequivalent or therapeutically equivalent to the innovator 
product or even the previous generic product. Changes in the appearance of medicines often 
confuse elderly patients and there is an unwillingness of some patients to move to a different 
brand of their regular medicines. This could result in a lack of adherence as often colour and 
appearance assist in identifying which medicines to take and when to take them.[50,126,127]  
This problem does not only affect the public sector. Generic medicines available to patients 
in the private sector also change. The private sector is driven by medical schemes and is also 
impacted when the lists of brands which are permitted and covered by the scheme are 
changed.[35] Besides medical aid schemes, community pharmacists may change their stock 
of generic medicines depending on prices. The ‘big chain’ pharmacies are probably more able 
to stock a wider variety of the same generic medicines, and hence access may be more 
consistent for a patient. However a community pharmacist should always be able to order a 
generic which is preferred by a patient or prescriber. 
                                                             
26  Medicines and Related Substances Act as amended (Act 101 of 1965) 
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The problem with switching between two generic products is that they are not necessarily 
interchangeable.[60] The use of different excipients, manufacturing processes and 
manufacturing equipment often results in changes in bioavailability.[22] Besides that, when 
looking at the bioavailability limits in South Africa, they range from 80% to 125% for AUC 
and range from 75% to133% for Cmax at a 90% confidence interval.[22,63] This potentially 
means that for the AUC significant differences in the API bioavailability could be permitted 
between two generic pharmaceutical products. A potential bioavailability difference of up to 
45% is possible.[22] While one generic product may have been registered after proving that it 
is has 120% bioavailability, another may have been registered which has 85% bioavailability. 
The need for a narrower reference range (perhaps at a 95% confidence interval) should 
possibly be considered for comparators in the registration of generic medicines. Where an 
innovator product (IP) is manufactured locally, perhaps this should be considered the most 
desirable reference standard and not FRPs. 
5.7 Concerns using FRPs 
The use of FRPs in establishing equivalence presents certain challenges that may be 
overlooked in the guidelines. Permitting the use of FRPs requires that the MCC closely 
monitor the sources of the FRPs used. Perhaps it would become necessary for the MCC to 
require that only one source of an FRP is used for each active pharmaceutical ingredient in 
generic medicines in an effort to create uniformity. Unfortunately, it was not possible in this 
study to determine what the sources of the different FRPs used were. This can be considered 
a limitation in this study. 
5.8 Concerns regarding dissolution testing 
Dissolution testing is commonly used as a ‘surrogate’ test for in vivo bioequivalence studies. 
It is not however always accurate in determining and predicting bioavailability and 
bioequivalence.[18,62] If dissolution testing alone were capable of establishing equivalence; 
there would be no need for in vivo bioequivalence tests. While the use of dissolution studies 
as a surrogate significantly reduces the time and cost involved in proving equivalence, it was 
developed initially as a quality assurance tool and to assist in the selection of chemical 
candidates for research.[18] It is not a prognostic tool for drug absorption.[66] 
Studies to establish in vitro-in vivo correlations through dissolution testing for modified 
release preparations are continuing.[128-130] This would mean that after doing in vitro 
dissolution studies, the therapeutic effects of the same product in vivo could be predicted. 
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This has not yet been established for modified release systems as they are present in the 
gastro-intestinal tract for a longer time and both fed and fasting conditions need to be 
considered.[129] Until sufficiently accurate guidelines can be determined for the use of in 
vitro-in vivo correlations for modified release preparations, in vitro dissolution testing cannot 
be used alone in determining therapeutic equivalence. Having determined the therapeutic 
equivalence of a particular dose of a modified release product however, it may then be 
permissible to use dissolution testing for other strengths of the same product.[65] 
5.9 Legal liability  
Pharmacists are the ‘custodians’ of medicines. They are responsible for their safe keeping as 
indicated in both the MARS and Pharmacy Acts. Given Section 22F of the MARS which 
obligates pharmacists to dispense generic medicines, the question arises as to whether a 
pharmacist could be held legally liable for dispensing such a generic medicine in the event 
that (serious) adverse drug reactions occur.[58] A liability suit could theoretically be based on 
the expectation that, even if a generic medicine had been registered by the MCC, the 
pharmacist had failed to ensure that the generic product that was substituted was indeed 
therapeutically equivalent to the prescribed or domestic innovator product. This requires that 
pharmacists unequivocally trust the MCC’s registration processes. If the package insert of a 
medicine were to provide details of the source of a generic medicine and/or the basis on 
which it was registered (e.g. the details of a FRP if used, and what other testing was used) 
perhaps pharmacists would be better equipped to confidently fulfil their legal obligations to 
patients. It is however ultimately a pharmacist’s professional responsibility that when 
substitution takes place, the product dispensed will be of same quality, safety and efficacy as 
the innovator product.[58,131] ‘Dispensing doctors’ and other dispensing health 
professionals are likewise responsible for the quality, safety and efficacy of the products they 
provide. A question that can then be asked is: ‘What difference would it make to dispensers 
and consumers if the package insert indicated that a FRP had been used for purposes of 
registration instead of a DRP?’ The consequences of providing this additional information 
would also have to be determined in terms of, inter alia, healthcare costs and adherence. 
5.10 PAIA 
The Promotion of Access to Information Act, even if technically used erroneously, proved to 
be useful in obtaining limited information. As neither the pharmaceutical companies nor the 
MCC were in fact obliged to respond to the requests, it is perhaps indicative of a sense of 
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‘goodwill’ towards the researcher, the institution or the profession that responses were 
obtained.  
Each private company is required to have a PAIA Manual.[100,102]27 Though these manuals 
were not requested nor inquired about in the study, and this is a limitation of the study, it was 
assumed that each of the companies would have had one. The three companies that did not 
respond may have done so because they were of the opinion that the requests were not up to 
the correct PAIA standards. Their lack of response therefore does not necessarily indicate a 
lack of transparency and a disregard of the Act as could otherwise have been assumed. 
Reasons documented elsewhere for failure to respond to PAIA requests include a lack of 
understanding of the Act, or lack of a protocol indicating how to deal with PAIA 
requests.[101,102] From a layperson’s perspective (‘at face value’) the PAIA seems to 
indicate that it provides ‘access to information’ when in fact it provides access to specified 
‘records’. This created an element of confusion in this study. It also makes the instrument 
user-unfriendly in some ways, and could even be said to not fully realise the promise in 
Section 32 of the Constitution of ‘the right of access to information’ (here not specified 
narrowly as ‘records’).  
The PAIA stipulates that requests are to be sent to the CEO for private bodies. However, the 
direct contact details of the CEOs are sometimes extremely difficult to obtain. Few CEOs 
publicly disclose their contact or email addresses. This difficulty explains the delay in 
submitting some of the initial requests in this study. If the PAIA is to be successful in 
promoting the openness and transparency that it stands for, the request process could be made 
simpler. The Act also stipulates that a particular right to information has to be stated in the 
request to private bodies. This may present a challenge as the right may not be an ‘official 
right’ according to the company receiving the request. Company I for example, in its second 
refusal of the request indicated that a right to academic endeavour was not in their view a 
legitimate constitutional right which warranted the release of information. This potentially 
presents a limitation to the access of information for research purposes.  
 
 
                                                             
27  The deadline for certain private companies to submit their manuals to the South African Human Rights 
Commission was extended to the 31 December, 2011, but this has subsequently again been extended to 31 
December 2015. This would not have applied to the manufacturing component of the pharmaceutical industry, 
as they have more than 50 employees and an annual turnover of more than R10 million. See: 
http://www.sahrc.org.za/home/21/files/EXTENSION%20GRANTED%2030122011.pdf   
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The MCC in a ‘General Information’ Guideline (2.01 March 2011) states: 
2.3 CONFIDENTIALITY/SECRECY 
The confidentiality of information submitted to the MCC is governed by Section 34 of the 
Act.  The MCC, committee members or staff of the Medicines Regulatory Affairs (MRA), 
may NOT  
• disclose to any person, any information acquired in the exercise of powers or performance 
of functions under the Act and relating to the business affairs of any person, except  
 for the purpose of exercising his/her powers, or for the performance of his/her 
functions under the Act, or  
 when required to do so by any competent court or under any law, or  
 with the written authority of the Director-General, or  
• use such information for self-gain or for the benefit of his employer.  
The MCC may insist on written confirmation of the identity and affiliation of an individual 
inquiring telephonically, or in person, about a medicine.  No information shall be disclosed 
telephonically unless the Medicines Control Officer knows the enquirer is entitled to receive 
the information. (emphasis in original) 
This is why no initial informal request was submitted to the MCC and the PAIA was used as 
a first resort. It is also why a request for the researcher to examine the records in the 
Department of Health itself was not even considered. The ‘Deputy Information Officer’ of 
the Department of Health legitimately refused the erroneously worded request both times, 
quoting from the PAIA. The MCC’s failure to furnish the PAIA Manual however is 
unacceptable considering that it meets the definition of a ‘public body’ in the Act, and in 
terms of Section 14 of the PAIA was required to have had a manual available within 6 
months of the commencement of Section 14 (which was announced on February 15, 2002)28. 
This failure is consistent with reports on how most public or State institutions do not have 
PAIA Manuals.[119] 
A large number of cases in which PAIA was found to have been successfully used were 
between companies and organisations. Political parties are also resorting to use the PAIA in 
significant ways.[132] The ‘layperson’ using the PAIA (without being trained in its use) is 
seemingly not as common an occurrence. While efforts have been made to increase access to 
PAIA by permitting its enforcement in Magistrate courts, this seems to be of no appreciable 
value if the ‘layperson’ is unable to use and apply the Act.[132] 
5.10.1 The experience of using PAIA as a ‘layperson’  
Making erroneous face value use of the PAIA as a layperson (e.g. as would a pharmacist in 
any setting) is a major finding of this study. Although the pharmaceutical companies that 
responded by providing the requested information may have had a similar interpretation of 
                                                             
28  Government Notice (R187), Government Gazette No. 23119. Proclamation by President of the 
commencement of sections 10.14.16 & 51 of PAIA. 15 February 2002.  
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the Act as the investigator, it is perhaps remarkable how much information they were 
prepared to voluntarily provide. It may also be assumed that the companies that did not 
respond to the request at all viewed the request as inappropriately worded.  
When submitting an application in terms of the PAIA, clear thought needs to go into 
determining the ‘legal right’ that is being protected by the information not being in the public 
domain, and the details of the exact record that is required. This is problematic when a 
request is for a record involving the registration procedure for a medicine – as the process is 
already legislated as ‘secret’. The forms used in the application for registration of a medicine 
changed from the MBR1 to the MRF1 some time after 2002. Which part of the MRF1 would 
a ‘layperson’ request? They would probably require assistance to use and apply the PAIA. 
How readily and freely available that assistance would be is a question in its own right. This 
can be highlighted as a limitation in the use of the PAIA for the ‘layperson’, and an obstacle 
in the promise of Section 32 of the Constitution. One should not need the assistance of a 
lawyer to use the PAIA. 
5.11 Summary 
As the MCC guidelines are providing a relatively flexible approach to generic medicines’ 
registration, it is possible that ‘irregularities’ regarding tests to prove equivalence may 
technically not be irregularities at all. The companies may, in correspondence with the MCC, 
have motivated for and been granted bio-waivers. This question was not asked. 
This study does not support a viewpoint that foreign reference products are not safe for use 
and/or cannot be used in practice. These products are, as indicated by Kanfer, prescribable 
and usable. They may however not be ‘interchangeable’ with the local innovator product and 
hence their use as comparators may be inappropriate. It follows that substitution of innovator 
products with generics registered against FRPs may then also be inappropriate. This is a 
potential ‘gap’ in the registration of generic medicines in South Africa. 
The MCC has complied with WHO requirements in terms of developing and providing 
standards and guidelines for use in medicines registration[1] although it is acknowledged that 
the WHO is not itself a regulatory authority. One of the recommendations made by the WHO 
regarding effective medicines regulation in general is to systematically monitor the regulatory 
process and to identify problems. This is said to include the regulatory authority becoming a 
‘learning organisation’.[1] (inverted commas added) Although there may be ethical 
implications for the public as ‘recipients’ of such ‘learning processes’, this study highlights 
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some areas that may need to be clarified, and some improvements and amendments that could 
potentially be made. 
The initial reasons for the use of generic medicines in SA (as in numerous other countries) 
were to help reduce the costs of healthcare. This goal was to be achieved without 
compromising the quality of the medicines used. The initial comparators for generic 
medicines were only the innovator products. Once consumers/patients are of the opinion or 
belief that generic medicines ‘do not work’, this could result in them opting for the more 
expensive brand products in settings where they have a choice – especially if there is a third 
party payer such as a medical aid. This would not reduce the cost of healthcare. Besides that, 
the health of consumers may be compromised. For example, sub-therapeutic concentrations 
from generics may result in a lack of a therapeutic effect; higher than recommended 
concentrations may lead to toxicity and other adverse drug reactions may be experienced. 
These problems may in and of themselves lead to increased healthcare costs. Some of these 
problems may be exacerbated because generics are no longer being registered only against 
innovator products; and because in vitro testing is being more frequently used to avoid the 
costs involved in in vivo testing.  
The process in using the PAIA correctly can be easily misinterpreted without the assistance 
of a person trained in its use, or without oneself being trained. This study highlights some of 
the errors made in attempting to use the PAIA independently. 
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Chapter 6: Conclusions 
 
6.0 Summary of the study 
The study was partly successful in meeting the objectives. The investigator was able to 
determine the approximate use of FRPs in the small sample of controlled release products (at 
least 50%). It was unsuccessful in identifying the use of FRPs and tests involved for the one 
BCS class IV product included as the company did not respond to the request. The study 
showed that for the specified sample, pharmaceutical companies were adherent to MCC 
guidelines and that the appropriate studies for registration were performed when required as 
evidenced by Table 4.3. The study succeeded in piloting the R-Score as a means of 
documenting the responses of the pharmaceutical companies. It could however be argued that 
the pharmaceutical companies would not have voluntarily provided the information they did, 
had it not been requested, even if erroneously, using the PAIA. As the request to the MCC for 
the provision of information was unsuccessful, it is not possible to validate the information 
provided by the pharmaceutical companies who voluntarily responded. 
The action research methodology successfully enabled the investigator to obtain information, 
reflect on the process, modify the approach, obtain more information and to draw conclusions 
and recommendations from the data collected.  
6.1 Conclusions 
Should prescribers and/or dispensers know when a foreign reference product has been used to 
register a generic medicine? The investigator is of the opinion that the answer to this question 
is ‘yes’. It is evident that FRPs are being used in the registration of generic medicines as at 
least ten of the twenty products and possibly more used FRPs in this case study. If prescribers 
and dispensers do not know whether FRPs were used (and related to that, what tests were 
done to prove equivalence) in the registration of generic medicines, they cannot make 
informed choices on behalf of their patients. As it is a legal obligation of the pharmacists to 
implement generic substitution according to the Medicines Act, being sure of equivalence is 
essential in the context of legal liability. The MCC has this information. The PAIA revealed 
that the records are kept as hard copies by the MCC, and that an easily accessible electronic 
database of pertinent information for all registered medicines is not available to them. 
Possible adjustments to the present system would need to include changes to the Regulations 
to the Medicines Act to provide for the additional proposed information about FRPs to be 
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included in package inserts (and possibly even the patient information leaflets – although this 
should be thoroughly debated first). When equivalence has been proven between a generic 
medicine and a reference product which is preferably the local innovator product (or a FRP 
that has been clinically proven to be therapeutically equivalent to the innovator product), 
dispensers could more confidently adhere to generic substitution as mandated in Section 22F 
of the Medicines Act. Dispensers’ (who are pharmacists) views on the acceptability of the use 
of FRPs for generic medicines registration is irrelevant as the law stands, and it is possible 
that through anecdotal reports of certain generics ‘not working’, they simply avoid dispensing 
them. 
Prescribers may choose to write ‘no substitution’ on their prescriptions if they are 
unconvinced that a generic registered against an FRP is acceptable. This could have 
consequences for healthcare costs. 
It is debatable as to whether or not the information about registration against a FRP would be 
of any particular benefit to members of the public. However if patients were informed, this 
would fulfil the NDP requirement that patients make an ‘informed decision’ about the use of 
a particular generic product. This begs the question as to how much information a patient 
needs in order to make an informed decision about medicines choices – a basic understanding 
of pharmacology?  
If comparative in vitro dissolution studies are on occasion being inappropriately being used 
alone for the registration of modified release preparations, this would be in direct 
contradiction with the MCC guidelines which indicate that in vivo bioequivalence studies are 
required for the registration of these preparations unless the product qualifies for a bio-
waiver.  
In terms of ‘responsiveness’, less than half of the companies voluntarily provided the full 
information. Of the four companies who provided all the information, two did so only after 
initially indicating that the information could not be disclosed. The PAIA, even in its 
erroneous usage, was partially effective in obtaining information from the private bodies but 
unsuccessful in doing so from the public body. The goal of the ‘right to access of 
information’ as stated in the Constitution that the PAIA is making provision for, has yet to be 
attained in South Africa in terms of medicines regulation in both private and public bodies – 
and not only should the access to information be revisited in terms of the PAIA, but the 
‘secrecy’ clause of the Medicines Act may need to be reformulated.  
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At present, as this study demonstrates, the only option is for prescribers, dispensers and the 
public to rely entirely on the MCC’s rigour in assessing applications for registration of 
modified release and other generic medicines.  
6.2 Recommendations 
• The MCC (or the new entity) should ensure that it has a PAIA manual readily 
available as specified in the PAIA. 
• An FRP should be used as a comparator to prove equivalence of generic medicines for 
registration purposes as a last resort – as indicated by the MCC Pharmaceutical and 
Analytical guideline, and only once it has been proven to be equivalent to the local 
innovator product.  
• If an FRP has been used to prove equivalence, consideration to making healthcare 
professionals, especially dispensers, (but possibly even the public) aware of this 
bearing in mind the possibility of unintended consequences.  
• Changing patients from one generic medicine to another should not be undertaken 
lightly as generic medicines are not necessarily therapeutically equivalent with each 
other. 
• The regulatory authority should ensure that guidelines for registration are strictly 
followed and that no ‘loopholes’ are possible. Some of the present guidelines should 
possibly be reformulated as regulations to the Medicines Act.  
• A culture of openness and transparency must be developed in both the regulatory 
authority and in pharmaceutical companies. The transparency does not need to be 
restricted to the use of FRPs only but also to the general functioning of these bodies. 
• The regulatory authority should ensure that all relevant records are captured 
electronically so that information can be more efficiently accessed by both it and 
those who request information. 
6.3 Possible future areas of research 
It would not be feasible (or reasonable) as stated by the DIO to take the MCC to court for 
their refusal to provide the requested information. Relatively good information can be 
obtained through having a parliamentary question asked – provided a member of parliament 
can be found who is prepared to ask it, and that the Member of Parliament asking the 
question formulates it correctly. Unfortunately the present party political system in South 
Africa makes it difficult to find individual (independent) members of parliament who are 
willing to ask parliamentary questions. 
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Research to establish the extent of the use of FRPs as comparators in the registration of 
generic medicines could be undertaken and the extent to which the FRPs have or have not 
been shown to be therapeutically equivalent to the innovator products. This research should 
include BCS class IV products.  
Research documenting problems, adverse drug reactions or effects that arise from the use of 
generics registered using FRPs would be useful. Anecdotal reports from patients, prescribers 
and dispensers of generic medicines that ‘don’t work’ could be used as a starting point. Such 
studies could document the actual effects (efficacy and effectiveness) of generics registered 
using a FRP comparator rather than the IP or even a DRP as comparator. A similar study 
could compare the therapeutic effectiveness and in vivo bioavailability between a group of 
patients receiving an innovator product, a group receiving a generic registered using the IP as 
a comparator and a group receiving a generic registered using a FRP as a comparator. 
Dissolution profiles for these three products could also be assessed and compared.  
It might be of interest to determine patients’ responses to knowing about generic medicines 
being registered using FRPs and if they would still choose to be substituted onto them even if 
the costs are reduced. Could knowing about FRPs have an adverse effect on adherence 
(compliance)? Pharmacists or dispensers could also be asked about their views or their 
perceptions of the risks of substituting a patient onto a generic medicine that may not have 
been proven to be equivalent to the local innovator product. 
Finally, a ‘layperson’s’ use of PAIA is not as straight forward as it would appear at face 
value. The fact that most of the companies approached were nevertheless prepared to provide 
relatively sensitive information is perhaps a tentative indicator that pharmaceutical companies 
are prepared to contribute to academic research in South Africa. The question remains 
however as to whether or not the companies would have responded had the requests for 
information not been asked using the PAIA. The fact that useful information was obtained 
even using the PAIA incorrectly possibly indicates that the PAIA is in and of itself a valuable 
tool. 
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Appendix 1: List of medicines that require data other than 
comparative dissolution data from circulars 14/89 and 14/95 
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Appendix 2: Request to pharmaceutical companies 
 
Faculty of Pharmacy 
Rhodes University  
P.O Box 94 
Grahamstown, 6140 
 
[Date] 
The Chief Executive Officer/ Information Officer 
[Address] 
 
Our ref: 0001/xxx/2011 
 
Dear  
REQUEST FOR INFORMATION IN TERMS OF THE PROMOTION OF ACCESS TO 
INFORMATION ACT REGARDING THE REGISTRATION OF GENERIC MEDICINES. 
My name is Eldinah Hwengwere. I am a student in the Faculty of Pharmacy at Rhodes University. I 
am studying towards a Masters degree. Please find attached a completed FORM C request for access 
to information as outlined in the Promotion of Access to Information Act 2 of 2000 (PAIA). In 
summary I would like to find out whether a Foreign Reference Product was used in the registration 
process of the following product which is manufactured and/or distributed by your company: 
• List of products 
I acknowledge the secrecy clause of section 34 of the Medicines and Related Substances Act. I am 
also aware that a fee is usually required, but am requesting exemption from payment on the basis of 
being a full time student and that the information will be used for academic and scholarly purposes 
only. I have attached to this letter a copy of my registration as a student and a signed letter from my 
supervisor.  
As recommended by the PAIA, please use the above reference number (0001/XXX/2011) in future 
correspondence. If there is any information that you are unable to provide, please could you give 
reasons as to why not. I am also in the process of applying for similar information from the MCC 
using the PAIA.  
 
Yours Faithfully 
 
Eldinah Hwengwere
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FORM C 
REQUEST FOR ACCESS TO RECORD OF PRIVATE BODY 
(Section 53(1) of the Promotion of Access to Information Act, 2000) (Act. No. 2 of 2000) 
[Regulation 10] 
A. Particulars of private body 
 
The Head:  
CEO name and company address 
 
 
B. Particulars of person requesting access to the record 
(a) The particulars of the person who requests access to the record must be given below. 
(b) The address and/or fax number in the Republic to which the information is to be sent must be 
given. 
(c) Proof of the capacity in which the request is made, if applicable, must be attached. 
 
Full names and surname: ELDINAH HWENGWERE 
 
Identity number: AN372419 (passport) 
 
Postal Address:  
FACULTY OF PHARMACY 
 RHODES UNIVERSITY 
 P.O BOX 94,       
GRAHAMSTOWN. 6140 
 
Fax Number: 0466361205 
Telephone number: 0729298387 
 E-mail Address: g06h3782@campus.ru.ac.za 
 
Capacity in which the request is made, when made on behalf of another person: N/A 
 
C. Particulars of person on whose behalf request is made 
This section must be completed ONLY ifs requests for information is made on behalf of another 
person. 
Full names and surname: ___________________________________ 
Identity number: __________________________________________ 
 
D. Particulars of record 
(a) Provide full particulars of the record to which access is requested, including the reference number 
if that is known to you, to enable the record to be located. 
(b) In the provided space is inadequate, please continue on a separate folio and attach it to this form.  
 
The requester must sign all the additional folios. 
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1. Description of record or relevant part of the record: 
 
COULD YOU PLEASE INFORM ME WHAT TESTS WERE DONE TO SHOW 
BIOEQUIVALENCE FOR REGISTRATION OF THE ATTACHED LIST OF 
GENERIC (MULTISOURCE INTERCHANGEABLE) MEDICINES, 
MANUFACTURED AND/OR DISTRIBUTED BY YOUR COMPANY AND PLEASE 
STATE WHETHER A DOMESTIC OR FOREIGN REFERENCE PRODUCT WAS 
USED. 
2. Reference number, if available:  
 
3. Any further particulars of record:  
 
E. Fees 
(a) A request for access to a record, other than a record containing personal information about 
yourself, will be processed only after a request fee has been paid. 
(b) You will be notified of the amount required to be paid as the request fee. 
(c) The fee payable for access to a record depends on the form in which access is required and the 
reasonable time required to search for and prepare a record. 
(d) If you qualify for exemption of the payment of any fee, please state the reason for exemption. 
 
Reason for exemption from payment of fees:  
 
INFORMATION IS TO BE USED FOR ACADEMIC AND SCHOLARLY PURPOSES ONLY.  
 
F. Form of access to record 
If you are prevented by a disability to read, view or listen to the record in the form of access provided 
for in 1 to 4 hereunder, state your disability and indicate I which form the record is required. 
Disability: N/A 
 
G. Particulars of right to be exercised or protected 
If the provided space is inadequate, please continue on a separate folio and attach it to this form. The 
requester must sign all the additional folios 
 
1. Indicate which right is to be exercised or protected. 
 
THE RIGHT OF ACCESS TO INFORMATION, AND THE RIGHT OF ACADEMIC 
AND SCHOLARLY ENDEAVOUR. 
 
2. Explain why the record requested is required for the exercise or protection of the 
aforementioned right 
 
THIS FORMS PART OF A POSTGRADUATE MASTERS DEGREE BY THESIS AT 
RHODES UNIVERSITY. 
 
H. Notice of decision regarding request for access: 
You will be notified in writing whether your request has been approved / denied. If you wish to be 
informed in another manner, please specify the manner and provide the necessary particulars to 
enable compliance with your request. 
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How would you prefer to be informed of the decision regarding your request for access to the 
record?          PLEASE EMAIL ME THE INFORMATION AT:    g06h3782@campus.ru.ac.za 
 
Signed at GRAHAMSTOWN             this 30th    day of      May 2011 
 
 
SIGNATURE OF REQUESTER 
 
Name of company:  
Trade name 
of product 
Chemical Entity FRP used 
for 
registration? 
 
(yes/no) 
Test(s) done to show equivalence 
with reference product for 
purposes of registration in SA 
List of product(s) Name of active 
pharmaceutical 
ingredient 
  
 
Our ref: 0001/xxx/2011 (as in cover letter) 
 
 
 
 
 99 
Appendix 3: First request to the MCC 
 
Faculty of Pharmacy 
Rhodes University 
P.O. Box 94 
Grahamstown. 6140 
 
24 May 2011 
Registrar of Medicines 
Medicines Control Council 
Private Bag X828 
Pretoria. 0001 
 
Our ref: 0001/MCC/2011 
 
Dear Mrs Hela 
REQUEST FOR INFORMATION IN TERMS OF THE PROMOTION OF ACCESS TO 
INFORMATION ACT REGARDING THE REGISTRATION OF GENERIC MEDICINES. 
My name is Eldinah Hwengwere. I am a student in the Faculty of Pharmacy at Rhodes University. I 
am studying towards a Masters degree. Please find attached a completed FORM A request for access 
to information as outlined in the Promotion of Access to Information Act 2 of 2000 (PAIA). I am 
interested in the use of foreign reference products in the registration of generic medicines. I noted that 
the Minister of Health did not address this question when it was asked in parliament. (Question No 
3021 - Internal Question Paper: 29 October 2010). The question was asked in relation to generic 
medicines registration ‘how many were used [registered] against foreign reference products as 
opposed to local innovator products?’ The answer given was that the MCC does not use generic 
products for comparative purposes. It appears as if there may have been a misunderstanding of what a 
foreign reference product is, and I would like to ask this question again, as well as to ask whether a set 
of twenty specific products were or weren't registered using a foreign reference product. 
I acknowledge the secrecy clause of section 34 of the Medicines and Related Substances Act. I am 
however requesting this information in the public’s best interest. The information I hope to receive 
from you/MCC will be used strictly for academic purposes. I have attached to this letter a copy of my 
registration as a student and a signed letter from my supervisor.  
As recommended by the PAIA, please use the above reference number (0001/MCC/2011) in future 
correspondence. If there is any information that you are unable to provide, I would appreciate your 
guidance in finding other sources from which the information could be made available. I will in any 
case be contacting the individual manufacturers. 
 
Yours Faithfully 
 
Eldinah Hwengwere
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FORM A 
REQUEST FOR ACCESS TO RECORD OF PUBLIC BODY 
(Section 18 (1) of the Promotion of Access to Information Act, 2000 
(Act No. 2 of 2000) 
[Regulation 2] 
 FOR DEPARTMENTAL USE 
       Reference number:___________ 
 
Request received by:_______________________________________________ 
 
(state rank, name and surname of information officer/deputy information officer) on 
____________________________(date) at____________________ (place). 
 
Request fee (if any): R……………………………. 
 
Deposit fee (if any):  R……………………………. 
 
Access fee:   R……………………………. 
       __________________________ 
       SIGNATURE OF INFORMATION  
     OFFICER/DEPUTY INFORMATION OFFICER 
A. Particulars of public body   
 
MEDICINES CONTROL COUNCIL 
PRIVATE BAG X828 
PRETORIA 
0001 
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B. Particulars of person requesting access to the record  
 
(a) The particulars of the person who requests access to the record must be recorded below. 
(b) Furnish an address and/or fax number in the Republic to which information must be sent 
(c) Proof of the capacity in which the request is made, if applicable, must be attached. 
 
Full names and surname: ELDINAH HWENGWERE 
Identity/Passport number: AN372419  
Postal address:  FACULTY OF PHARMACY, RHODES UNIVERSITY, PO 
BOX   94, GRAHAMSTOWN. 6140 
Fax number:                0466361205 
Telephone number:                0729298387 
E-Mail Address    g06h3782@campus.ru.ac.za  
Capacity in which request is made, when made on behalf of another person:  N/A 
 
A. Particulars of person on whose behalf request is made 
 
This section must be completed ONLY if a request for information is made on behalf of 
another person.  
 
Full names and surname:   
Identity number:    
   
D. Particulars of record  
(a) Provide full particulars of the record to which access is requested, including the  reference 
number if that is known to you, to enable the record to be located.  
(b) If the provided space is inadequate please continue on a separate folio and attach it to this 
form.  The requester must sign all the additional folios.  
 
1. Description of record or relevant part of the record: 
i. HOW MANY GENERIC MEDICINES WERE REGISTERED 
AGAINST FOREIGN REFERENCE PRODUCTS BETWEEN 2007 
AND 2010 AS OPPOSED TO BEING REGISTERED AGAINST 
LOCAL INNOVATOR PRODUCTS? [PLEASE NOTE THAT THIS 
QUESTION WAS INCORRECTLY ANSWERED IN THE 
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PARLIAMENTARY INTERNAL QUESTION PAPER NO 34, 
QUESTION 3021, 29 OCTOBER 2010.] 
ii. COULD YOU PLEASE INFORM ME WHAT TESTS WERE DONE 
TO SHOW BIOEQUIVALENCE FOR REGISTRATION OF THE 
ATTACHED LIST OF 20 GENERIC (MULTISOURCE 
INTERCHANGEABLE) MEDICINES, AND FOR EACH, WHETHER 
A DOMESTIC OR FOREIGN REFERENCE PRODUCT WAS USED. 
2. Reference number, if available:  
3. Any further particulars of record: 
E. Fees 
(a) A request for access to a record, other than a record containing personal information 
about yourself, will be processed only after a request fee has been paid.  
(b) You will be notified of the amount required to be paid as the request fee. 
(c) The fee payable for access to a record depends on the form in which access is required 
and the reasonable time required to search for and prepare a record.  
(d) If you qualify for exemption of the payment of any fee, please state the reason for 
exemption.   
 
Reason for exemption from payment of fees:         I DO NOT EARN A SALARY. 
F. Form of access to record  
If you are prevented by a disability to read, view or listen to the record in the form of access 
provided for in 1 to 4 hereunder, state your disability and indicate in which form the record is 
required.  
Disability: _________________ 
_________________________ 
Form in which record is required: _______ 
__________________________________ 
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Mark the appropriate box with an ‘X’. 
NOTES: 
(a) Your indication as to the required form of access depends on the form in which the 
record is available. 
(b) Access in the form requested may be refused in certain circumstances. In such a                   
          case you will be informed if access will be granted in another form.  
(c)      The fee payable for access to the record, if any, will be determined  
          partly by the form in which access is requested. 
1.     If the record is in printed form: 
   Copy of record*    Inspection of record 
2.    If record consists of visual images: 
      (this includes photographs, slides, video recordings, computer-generated 
       images,sketches, etc). 
 view the images   
 
copy of the images* 
               
 transcription of the 
images* 
3.    If record consists of recorded words or information which can be reproduced in 
sound: 
 Listen to the 
soundtrack (audio 
cassette) 
             
          
   
transcription of soundtrack* 
(written or printed document) 
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4. If record is held on computer or in an electronic or machine –  
    readable form: 
 
 
Printed copy of 
record* 
 Printed copy derived 
from the record* 
 
 
copy in computer readable 
form*(stiffy or compact disc) 
  
* If you requested a copy or transcription of a record (above), do you wish the 
copy or transcription to be posted to you? 
 
A postal fee is payable.  
YES  
 
 
 NO    
  
 
Note that if the record is not available in the language you prefer, access may be granted in the 
language in which the record is available.  
In which language would you prefer the record?                                    
 
A. Notice of decision regarding request for access  
You will be notified in writing whether your request has been approved/denied.  If you wish to 
be informed thereof in another manner, please specify the manner and provide the necessary 
particulars to enable compliance with your request.  
 
How would you prefer to be informed of the decision regarding your request for access to the 
record? PLEASE EMAIL ME THE INFORMATION AT g06h3782@campus.ru.ac.za 
Signed at      GRAHAMSTOWN                    this    the 24th  day of   MAY             2011                                                                                                     
 
SIGNATURE OF REQUESTER 
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1. How many generic medicines were registered against foreign reference products between 
2007 and 2010 as opposed to being registered against local innovator products? [Please note 
that this question was incorrectly answered in the parliamentary internal question paper no 34, 
question 3021, 29 October 2010.] 
 
2. Please fill in the following table: 
 
Product Trade 
Name 
Chemical Entity Manufacturer 
(Holder of 
certificate of 
registration of 
product) 
Foreign 
product 
used? 
Tests done to show 
equivalence with reference 
product for purposes of 
registration 
List of 20 
products 
Specific active 
ingredient in product 
Companies for 
each respective 
product 
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Appendix 4: Parliamentary Question  
*QUESTION NO. 3021* 
 
*DATE OF PUBLICATION IN INTERNAL QUESTION PAPER: 29 October 2010   * 
 
*(INTERNAL QUESTION PAPER NO. 34)* 
 
*Mrs J F Terblanche (DA) to ask the Minister of Health:* 
 
 
(1)  Whether any generic medicines were registered (a) in (i) 2007,(ii) 2008 and (iii) 2009 
and (b) since 1 January 2010; if so, (aa) how many in each case, (bb) how many were used 
against foreign reference products as opposed to local innovator products and (cc) what 
percentage of total registrations in each specified period were generic medicines; 
 
(2) How many new chemical entities were registered in each specified 
period? 
REPLY 
 
(1)  Yes 
(a), (b), (aa) and (cc): The following table reflects the details in this regard 
Year Number of generic medicines 
registered 
Percentage of total registration 
2007 359 92.76 
2008 434 89.85 
2009 472 90.42 
2010 (October) 283 92.33 
 
(bb)       MCC does not use generic products for comparative purposes. 
(2)        The following table reflects details in this regard 
Year  Number of new chemical entities registered 
2007 7 plus 12 various strengths 
2008 12 plus 11 various strengths 
2009 14 plus 20 various strengths 
2010 (1 October) 9 plus 4 various strengths 
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Appendix 5: Letter sent to unresponsive companies 
Faculty of Pharmacy 
Rhodes University  
P.O Box 94 
Grahamstown, 6140 
 
19 August 2011 
The Chief Executive Officer/ Information Officer 
[Address] 
Our ref: 0001/XXX/2011 
Dear [Name] 
 
REQUEST FOR INFORMATION IN TERMS OF THE PROMOTION OF ACCESS TO 
INFORMATION ACT REGARDING THE REGISTRATION OF GENERIC MEDICINES. 
As indicated in previous correspondence dated 1 June 2011, my name is Eldinah Hwengwere and I 
am a postgraduate student at Rhodes University. You acknowledged the receipt of my request but I 
have not yet received a response to the request in terms of the Promotion of Access to Information 
Act (Act 2 of 2000). According to Section 56 of the Act, a response to a request must be given within 
30 days. For your convenience this section is quoted below. 
Decision on request and notice thereof 
56. (1) Subject to Chapter 5 of this Part, the head of the private body to whom the request is 
made must, as soon as reasonably possible, but in any event within 30 days, after the 
request has been received or after the particulars required in terms of section 53(2) have 
been received— 
 
(a) decide in accordance with this Act whether to grant the request; and 
(b) notify the requester of the decision and, if the requester stated, as contemplated in section 
53(2)(e), that he or she wishes to be informed of the decision in any other manner, inform him 
or her in that manner if it is reasonably possible. 
 
I believe I have provided all the particulars required by section 53(2) but I would be happy to 
elaborate more fully on my request should that be needed in order for you to make a decision about 
my request. In terms of section 53(2)(e) I requested that I be informed by email. 
I have to the best of my knowledge met all the requirements of the application I have made. I am 
however also attaching an undertaking of confidentiality for your information. I am therefore 
requesting your official response to my formal application for information dated 1 June 2011. 
 
Kind regards 
 
Eldinah Hwengwere
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Appendix 6: Confidentiality undertaking 
 
RHODES UNIVERSITY 
-
Confidentiality undertaking 
FACULTY OF PHARMACY 
T-': 046 603 8381 • f lJC: ()04~ 636 1205 
P 0 Bo~ 9<1, Grall.omstown , 6140 
... "",11: dun.pha.macy+ru.ac.:tI 
I. Eldinah Hwengwere (1m 11 Masters student at Rhodes Univen;i!y. GrnhamstoWll. I am 
conducling research on the use of foreign reference products in South Africa for Ihe pUJl)05eS 
of registration of generic/mulli SQllKe products. ! have approached your company for 
infonna(ion regarding the registration of some of your generic products. The information that 
will be provided is strictly for my research for my Masters degree. 
r undenake not 10 disclose the name of your company or Ihe name of the generi<; products 
used in Ihe study. Pseudonyms have been devised (0 refer to companies and the products for 
purposes of publication in order to protect the interests of (he participant CQmpanies. I can 
make these pseudonyms available on request. 
Signed at: GRAHAMSTOWN Dale: 19 August 2011 
Student: Eldinah Hwengwere 
Supervisor: Professor Roy Jobson 
Dean of Faculty of Phannacy: Professor R. B. Walker 
 109 
Appendix 7: List of codes designated to companies and 
products 
 
Company Products Pharmacological nature of API 
A A1 Affects bone metabolism 
B B1 Anti-cholesterol 
 B2 Vasodilator 
 B3 Anti-depressant 
C C1 Anti-epileptic 
 C2 Anti-hypertensive 
 C3 Anti-hypertensive 
 C4 Mineral supplement 
 C5 Analgesic 
 C6 Anti-arrhythmic 
D D1 Analgesic 
E E1 Antibiotic 
F F1 Anti-inflammatory 
G G1 Anti-arrhythmic 
 G2 Anti-inflammatory 
 G3 Anti-epileptic 
H H1 Anti-hypertensive 
I I1 Anti-obesity 
 I2 Anti-epileptic 
 I3 Alpha-adrenoreceptor antagonist 
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Appendix 8: Company F – Second response 
Faculty of Pharmacy 
Rhodes University 
P.O. 90)(94 
Grahamstown, 6140 
13 July 201 I 
Ref: 00011 
medicines 
2011 Request (or information regarding the registration of generic 
Dear Eldinah Hwengwere, 
Herewith a response to your additional request: 
In line with the guidelines for the registration of medicines publisbed and distributed by the 
MeC (www.IDCCza.com). a solid oral dosage form such as a tablet or capsule will require 
bioequivalence studies as proof of comparative efficacy with the innovator unless a biowaiver 
can be supported. 
It is also a requirement of these guidelines, that if a foreign reference product is used in sucb 
studies, equivalence must be demonstrated between the study product, the foreign referen<:e 
product, and a product registered in Soutb Africa containing tbe same API. This equivalence will 
usually be confirmed by dissolution testing. 
As such, if a foreign reference product was used in the registration of a generic medicine, it 
follows that both a bioequivalence and dissolution smdy has been conducted. 
Going forward with your research, as a suggestion; a familiarity with the guidelines relevant to 
the topic you are investigating will aid yOu greatly in understanding tbe information you are 
requesting and assimilating. 
Kindly provide an original signature below, and return to acknowledge receipt. 
Thank you and kind regards, 
Regulatory Phannacist 
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Appendix 9: Company I – Final refusal 
Ms Eldinah Hwengwere 
Faculty of Pharmacy 
Rhodes University 
PO. Box 94 
Grahamstown, 6140 
Your ref: 0001, 2011 
Dear Ms Hwengwere 
22 September 2011 
REQUEST FOR INFORMATION IN TERMS OF THE PROMOTION OF ACCESS TO 
INFORMATION ACT REGARDING THE REGISTRATION OF GENERIC 
MEDICINES 
Your letter dated 19 August 2011 has reference. 
As stated in our previous correspondence of 3 June 2011 , we reserved our right to 
comment on the vatidity of your request in terms of Act 2 of 2000. We have been 
advised that your request is not consistent with the intention of the Act, nor does il 
conform to the requirements of the Acl as you, inter alia, fail to explain which rights 
you are exercising or protecting as: 
a) 
b) 
the right of Access to Information cannot on its own, within the context of 
the Act, grant you access 10 our or any other private body's records. In this 
respect we refer you to Section 32 of Ihe Constitution which clearly 
stipulate the intention of this right; 
th~right, "academic and scholarly endeavour" (as recorded in your initial 
re~'1est) is not a recognised right in terms of the Constitution, 
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Appendix 10: MCC First refusal 
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, 
"TIIO wee OOES lOOT lISE OE~RIC PROOOCl S FOR COMPNtlTM PUflPOSES' 
The ~ogiott.. 01 ... """,*,,,!Nt the ~ _ ."....."..-, Tbe qoabon_ .... 
--~" ' .. _'" .... --""---.. - ........ 
----", 
The wee ..... ___ r-o..- _ ... _ SucIo i D" .',,,/Oin Il1O 
pIO<Iv« l;1oo_ .... ........, .. h>o<I_, 1 "" ur;:c_ ... _ ... , _"''''' 
!tlrougI1-" Il1o lot ... ,... <:IIOol .. " II h_ ... ,Oft,_.,. _ ... _._ 
~"'00l v __ ., ... 10<0 _t. ..... oI_.(5jbl"' ... At:t. 
"-2: "",.""'., r '1""'_ ",.~,*_"'''''''OI_.or_ ... __ 
1'<'1 __ 1"" ___ """'_100 ..... __ ....... 01.".1'1 .. ' .... ,,,,_ 
10 '_.0.:1, 2QOO, kWlI'WI_ . 
..,.,. 
R G J WISSING 
DEPUTY IHFORMAllOfl ""fleER 
DATE: 15/"7/11 
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Appendix 11: MCC Internal appeal 
 
Faculty of Pharmacy 
Rhodes University 
P.O. Box 94 
Grahamstown, 6140 
 
05 September 2011 
Registrar of Medicines 
Medicines Control Council 
Private Bag X828 
Pretoria. 0001 
 
Our ref: 0001/MCC/2011 
Dear Mrs Hela 
INTERNAL APPEAL: REQUEST FOR INFORMATION IN TERMS OF THE PROMOTION 
OF ACCESS TO INFORMATION ACT REGARDING REGISTRATION OF GENERIC 
MEDICINES. 
1. As indicated in my previous communication, dated 24 May 2011, my name is Eldinah Hwengwere 
and I am a Masters student at Rhodes University. My request for Information regarding the use of 
foreign reference products and the tests involved to prove equivalence for the registration of generic 
products was refused. I am therefore making a formal Internal Appeal in terms of Section 74 of the 
Promotion of Access to Information Act (Act 2 of 2000). 
2. I would also like to request a copy in terms of Section 14(3) of the Promotion of Access to 
Information Act, (Act 2 0f 2000) of the MCC’s Information Manual (which is required to have been 
compiled in terms of Section 14 (1) of the Promotion of Access to Information Act, (Act 2 of 2000). 
Please may I have the copy sent to me electronically at: g06h3782@campus.ru.ac.za  
I have attached to this letter; the prescribed Form B which outlines my grounds for appeal and 
relevant annexures i.e. the initial request and the response I received refusing my request. As can be 
seen from the date of the refusal 13/07/2011 my appeal falls well within the 60 days required by 
Section 75(1)(a)(i) of the Act. 
As no fee was required for my initial request, because I am a student, I am assuming that no fee will 
be required for this appeal. 
I look forward to your response. 
Kind regards 
 
Eldinah Hwengwere 
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FORM B 
NOTICE OF INTERNAL APPEAL 
(Section 75 of the Promotion of Access to Information Act, 2000 (Act No. 2 of 2000)) 
[Regulation 8] 
Reference Number: 0001/MCC/2011 
A. Particulars of public body 
The Information Officer: 
MRS HELA 
MEDICINES CONTROL COUNCIL 
PRIVATE BAG X828 
PRETORIA 
 
B. Particulars of requester/third party who lodges the internal appeal 
(a) The particulars of the person who is lodging the internal appeal, must be completed below. 
(b) Proof of the capacity in which appeal is lodged, if applicable, must be attached. 
(c) If the appellant is a third person and not the person who originally requested the information, the 
particulars of the requester must be stated at C below.  
Full names and surname : ELDINAH HWENGWERE 
Identity number   : AN372419 (passport) 
Postal address   : FACULTY OF PHARMACY, RHODES UNIVERSITY, P.O.BOX  
                                                      94, GRAHAMSTOWN, 6140  
Fax number   : 0466361205 
Telephone number  : 0729298387 
E-mail address   : g06h3782@campus.ru.ac.za   
 
Capacity in which an internal appeal on behalf of another person is lodged:  N/A
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C. Particulars of requester 
This section must be completed ONLY if a third party (other than the requester) is lodging the 
internal appeal.  
Full names and surname : …………………………………………………………. 
Identity number   : …………………………………………………………. 
  
D. The decision against which the internal appeal is lodged 
Mark the decision against which the internal appeal is lodged with an ‘X’ in the appropriate box:  
 
X Refusal of request for access.  
   Decision regarding fees determined in terms of section 22 of the Act.  
   Decision regarding the extension of the period within which request must be dealt with 
in terms of section 26(1) of the Act.  
   Decision in terms of section 29(3) of the Act to refuse access in the form as requested 
by the requester.  
   Decision to grant request for access.  
 
E. Grounds for appeal 
If the provided space is inadequate please continue on a separate folio and attach it to this form. 
You must sign all the additional folios.  
State the grounds upon which the internal appeal is based:  
PLEASE FIND GROUNDS FOR INTERNAL APPEAL ATTACHED AS ANNEXURE A 
 
F. Notice of decision on appeal 
You will be notified in writing of the decision on your internal appeal. If you wish to be informed 
thereof in another manner, please specify the manner and provide the necessary particulars to 
enable compliance with your request.  
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State the manner: PLEASE GIVE A WRITTEN RESPONSE THROUGH EMAIL 
Particulars of manner:  g06h3782@campus.ru.ac.za  
Signed at: GRAHAMSTOWN                     this 29th      day of August                              of 2011  
 
SIGNATURE OF APPELLANT 
 
Annexure A
FOR DEPARTMENTAL USE: 
OFFICIAL RECORD OF INTERNAL APPEAL: 
Appeal received on (date) by (state rank, name and surname of information officer/deputy 
information officer). 
Appeal accompanied by the reasons for the information officer/deputy information officer's decision 
and, where applicable, the particulars of any third party to whom or which the records, submitted by 
information officer/deputy information officer on (date) to the relevant authority. 
OUTCOME OF APPEAL: 
DECISION OF INFORMATION OFFICER/DEPUTY INFORMATION OFFICER 
CONFIRMED/SUBSTITUTED BY NEW DECISION 
NEW DECISION:  
DATE RELEVANT AUTHORITY 
DATE RECEIVED BY THE INFORMATION OFFICER/DEPUTY INFORMATION OFFICER FROM 
THE RELEVANT AUTHORITY:  
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Grounds for Internal Appeal 
Appeal Pursuant to the Promotion of Access to Information Act, Act 2 of 2000 
The appellant is Eldinah Hwengwere and this appeal is directed to the Registrar of the Medicines Control 
Council (MCC). The Registrar is the relevant authority in terms of Section 74 of the Promotion of Access to 
Information Act (PAIA) to decide an appeal. On the 24th of May, the appellant made a formal request in terms 
of PAIA to the MCC. The request was for records relating to the reference products and tests involved in 
establishing equivalence of generic medicines for purposes of registration. A copy of this request is attached to 
this appeal and is marked as Annexure B. 
In a letter dated 13/07/2011, the MCC’s Deputy Information Officer, Mr. G J Wissing, wrote to the appellant to 
advise that the request had been refused in terms of Section 45(b) of PAIA. A copy of this letter is annexed to 
this appeal as Annexure B. The appellant does not accept the reasons given as adequate grounds for refusal and 
submits this appeal to the Registrar in terms of Section 74 of PAIA. 
The appellant contends that Section 45(b) of PAIA is not a valid basis for refusing this request for the following 
reasons:  
1. It is not unreasonable to anticipate that the Regulatory Authority should be able to access the product 
files of any product at any given time. 
2. Section 15(7) of the Medicines and Related Substances Act (Act 101 of 1965) states that:  
Any registration under this section, including the registration of medicines already registered . . . 
may be made subject to such conditions as may with regard to the succeeding provisions of this 
section be determined by the council. 
As every medicine is registered with ‘conditions of registration’ it must mean that should any query 
about the basis for a particular condition of registration be raised, the MCC can at any time access the 
product files (dossier) of a medicine’s application. Accessing the product files would therefore surely 
be a normal part of the regulatory authority's everyday activities and Section 45(b) of the PAIA (Act 2 
of 2000) would not apply. For example, a standard set of conditions which accompany a certificate of 
registration would include the following: 
• The applicant shall ensure that the medicine is manufactured and controlled in terms of the 
current Good Manufacturing Practices as determined by the Council 
• The manufacture of this medicine is subject to regular investigation and inspections by the 
inspectors appointed in terms of Section 26 of the Act, to assess compliance with current 
Good Manufacturing Practices. 
• The information in the package insert shall be updated on a regular basis to conform to the 
package insert recently approved by the Council. 
• The applicant must comply with all the legal requirements of the Medicines and Related 
Substances Act, 1965 (Act 101 of 1965). 
• The registration of this medicine shall be subject to review at intervals as determined by 
Council regarding its quality, safety and efficacy, and the registration of this medicine may be 
varied subject to issues Council may deem fit. 
• The first two production batches must be fully validated in terms of the detailed process 
validation protocol submitted at the time of the application for registration, and the validation 
report must be submitted within a month after completion of validation. 
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3. Section 15(7) of the Medicines and Related Substances Act, (Act 101 of 1965) mentioned above is 
further supported by Regulations 23(1)(j) and  26(1)(10) of the Medicines and Related Substances Act 
101 of 1965. The Regulatory Authority should surely be able at any time to verify the reasons for any 
conditions of registration 
1. Section 46 of PAIA indicates that disclosure of information is a requirement if the information is in the 
public’s best interest, see below: 
46. Despite any other provision of this Chapter, the information officer of a public body must 
grant a request for access to a record of the body contemplated in section 34(1), 36(1), 37(1)(a) or 
(b), 38(a) or (b), 39(1)(a) or (b), 40, 41(1)(a) or (b), 42(1) or (3), 43(1) or (2), 44(1) or (2) or 45, if— 
(a) the disclosure of the record would reveal evidence of— 
(i) a substantial contravention of, or failure to comply with, the law; or 
(ii) an imminent and serious public safety or environmental risk; and 
(b) the public interest in the disclosure of the record clearly outweighs the harm contemplated in 
the provision in question. 
 
In general, it is in the public’s best interest for prescribers and dispensers to know which generics have 
been registered against a Domestic Reference Product (DRP) and which generics have been registered 
against a Foreign Reference Product (FRP). This is particularly important in view of Section 22F(1)(b) 
of the Act which mandates the dispensing of generic medicines. It is important information for 
prescribers in terms of Section 22F(4)(a) of the Act who may not wish to have a generic registered 
against a foreign reference product dispensed. 
2. The selected companies have already been approached to participate in the study by responding to the 
same questions posed to the Council. However validation of the responses given will come from the 
information received from the Council.  
3. The names of the companies and products involved in the study have been assigned pseudonyms to 
conceal their identities in all publications 
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Appendix 12: MCC Second refusal 
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Appendix 13: MCC PAIA Manual request 
Faculty of Pharmacy 
Rhodes University 
P.O. Box 94 
Grahamstown, 6140 
 
25 October 2011 
 
Deputy Information Officer 
Private Bag X828 
Pretoria, 0001 
Our ref: 0001/MCC/2011 
 
Dear Mr Wissing 
RE: ACKNOWLEDGEMENT OF DECISION OF INTERNAL APPEAL 
I would like to acknowledge and thank you for the response I received from you dated 21 October 
2011. The decision to refuse the request in terms of Section 45(b) and Section 36 of the Promotion of 
Access to Information Act, (Act 2 of 2000) has been noted. 
As a follow-up, I would like to enquire about the second part of the request I made in the Internal 
appeal which was regarding a request for a copy of the MCC’s Information Manual (which is required 
to have been compiled in terms of Section 14 (1) of the Promotion of Access to Information Act, (Act 
2 of 2000). Please may I have the copy sent to me electronically at: g06h3782@campus.ru.ac.za 
I look forward to your response. 
 
Kind regards 
 
Eldinah Hwengwere 
 
 
